Lipid nanoparticles for inducing immune responses

By optimizing the composition and structure of lipid nanoparticles, especially the ratio of conjugated lipids, phospholipids, and ionizable lipids, the biodistribution and immune response issues of existing lipid nanoparticles in vaccine delivery were solved, achieving efficient antibody production and reducing side effects.

CN123076375APending Publication Date: 2026-11-10GENEVANT SCI GMBH
View PDF 25 Cites 0 Cited by

Patent Information

Application Number
CN202580026324.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-04
Filing Date
2025-04-02
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing lipid nanoparticles, when used for vaccine delivery, suffer from uneven biodistribution, high clearance rate, induction of undesirable immune responses and off-target effects, leading to increased side effects and low delivery efficiency, making it difficult to elicit high levels of antibody responses.

Method used

Lipid nanoparticles composed of conjugated lipids, phospholipids, ionizable lipids, and cholesterol in specific proportions are used to optimize the particle structure by adjusting the relative amounts and charge properties of the lipid components in order to improve the immunostimulatory effect of vaccines.

Benefits of technology

It significantly improved the strength of the vaccine's immune response, enhanced antibody production, reduced side effects, and achieved more effective targeted delivery and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076375A_ABST
    Figure CN123076375A_ABST
Patent Text Reader

Abstract

This disclosure provides lipid nanoparticles that are particularly beneficial for inducing an immune response in subjects, especially by stimulating the subjects to produce antibodies. The lipid nanoparticles may include one or more of the following: low concentrations of conjugated lipids, neutral phospholipids, and concentrations of ionizable lipids and / or sterols that satisfy certain thresholds depending on the concentration of the conjugated lipids. This disclosure also provides vaccines, other pharmaceutical compositions, and methods comprising the provided lipid nanoparticles.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to related applications

[0002] This application claims priority to U.S. Provisional Application No. 63 / 574,476, filed April 4, 2024, the entire disclosure of which is incorporated herein by reference for all purposes. Background Technology

[0003] Lipid nanoparticles (LNPs) have become a key technology in drug delivery, particularly for the encapsulation and systemic delivery of nucleic acids such as mRNA and siRNA. Their importance lies in their ability to protect these therapeutic agents from degradation, enhance cellular uptake, and control the release of encapsulated drugs. For example, lipid nanoparticles have emerged as a promising technology for vaccine delivery. These particles can, for instance, protect immunogenic nucleic acids (such as mRNA molecules) from degradation, facilitate their intracellular delivery, and promote endosome escape, thus enabling the translation of mRNA into target proteins, such as antigen proteins.

[0004] However, despite their success, there is an urgent need for improved LNPs, including those for delivering prophylactic vaccines. Current LNPs may have limitations, including suboptimal biodistribution and / or clearance rates, induction of undesirable immune responses, potential off-target effects, and low expression efficiency of the delivered payload (e.g., mRNA). For example, inflammation-related side effects such as pain, swelling, fever, and drowsiness may be associated with some current RNA-LNP-based vaccines. Furthermore, some LNP designs may unintentionally induce high levels of mRNA expression in off-target tissues and organs, thereby reducing prophylactic efficiency and increasing the likelihood of undesirable side effects. Therefore, developing next-generation LNPs with, for example, enhanced stability, targeted delivery, and minimized side effects is important for fully realizing the potential of LNPs in nucleic acid delivery for both prophylactic and therapeutic care. This disclosure addresses these needs and provides associated and other advantages. Summary of the Invention

[0005] This summary provides a high-level overview of various aspects of this disclosure and introduces some concepts described and illustrated in this document and the accompanying drawings. This summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used alone to define the scope of the claimed subject matter. The embodiments covered by this disclosure are defined by the claims rather than by this summary. The subject matter should be understood by referring to appropriate portions of the specification throughout, any or all of the drawings, and each claim. Some exemplary embodiments of this disclosure are described in detail below.

[0006] On one hand, this disclosure provides a vaccine comprising lipid nanoparticles. The lipid nanoparticles comprise conjugated lipids. The conjugated lipids constitute no more than X mol% of the total lipids of the lipid nanoparticles, wherein the value of X is no more than 1. The lipid nanoparticles further comprise phospholipids or pharmaceutically acceptable salts thereof. The phospholipids have a net neutral charge at physiological pH. The lipid nanoparticles further comprise ionizable lipids or pharmaceutically acceptable salts thereof. The lipid nanoparticles further comprise cholesterol or derivatives thereof. The lipid nanoparticles further comprise nucleic acids encoding a protein of interest (e.g., an antigen) or fragments thereof. The composition of the lipid nanoparticles satisfies at least one of the following conditions: (a) the ionizable lipids or pharmaceutically acceptable salts thereof constitute at least Y mol% of the total lipids of the lipid nanoparticles, wherein the value of Y is defined by the formula: 51.1 - 5.7X + 8.0X 2 (b) The cholesterol or its derivatives constitute no more than Z mol% of the total lipids in the nanoparticles, wherein the value of Z is defined by the following formula: 39.3 + 2.3X - 5.6X 2 .

[0007] On the other hand, this disclosure provides a method for generating lipid nanoparticles. The method includes providing an aqueous solution comprising a nucleic acid encoding a protein of interest (e.g., an antigen) or a fragment thereof. The method further includes providing an alcohol solution containing an alcoholic organic solvent, a conjugated lipid, an ionizable lipid or a pharmaceutically acceptable salt thereof, cholesterol or a derivative thereof, and a phospholipid or a pharmaceutically acceptable salt thereof. The phospholipid has a net neutral charge at physiological pH. The method further includes combining the aqueous solution and the alcohol solution to generate a lipid nanoparticle solution containing the lipid nanoparticles. The conjugated lipid accounts for no more than X mol% of the total lipids in the alcohol solution, where X is no more than 1. The composition of the alcohol solution satisfies at least one of the following conditions: (a) the ionizable lipid or its pharmaceutically acceptable salt accounts for at least Y mol% of the total lipids in the alcohol solution, where the value of Y is defined by the formula: 51.1 - 5.7X + 8.0X 2 (b) the cholesterol or its derivatives constitute no more than Z mol% of the total lipids in the alcoholic solution, wherein the value of Z is defined by the following formula: 39.3 + 2.3X - 5.6X 2 .

[0008] On the other hand, this disclosure provides a method for inducing an immune response in a subject against a protein of interest (e.g., an antigen) as described herein in a vaccine. The method includes administering a therapeutically effective amount of the vaccine to the subject.

[0009] On the other hand, this disclosure provides a method for preventing or treating a disease in a subject. The method includes administering a therapeutically effective amount of a vaccine as disclosed herein to the subject. Attached Figure Description

[0010] Figure 1 A graph depicting anti-HA IgG levels 28 days after immunization with 10 µg HA LNP containing various levels of PEG-lipids and ionizable lipids is presented. N = 4 BALB / c mice, SEM. LNP compositions are described in Table 1.

[0011] Figure 2 The graphs depict anti-OVA IgG levels 35 days after primary / booster immunization with 1 µg HA LNP containing various levels of PEG-lipids and ionizable lipids on days 1 and 21 are presented. N = 4 BALB / c mice, SEM. The LNP compositions are described in Table 2.

[0012] Figure 3 A graph depicting anti-HA IgG levels 28 days after immunization with 1 µg HAmRNA-LNP containing substituted mol% PEG-lipids and different cationic lipids is presented. N = 4 BALB / c mice, SEM. The LNP compositions are described in Table 3.

[0013] Figure 4 A graph depicting anti-HA IgG levels 28 days after immunization with 10 µg HA LNP containing different mol% conjugated lipids is presented. N = 4 BALB / c mice, SEM. The LNP compositions are described in Table 4. Detailed Implementation

[0014] A. Introduction

[0015] This disclosure generally relates to lipid nanoparticles that, when used, for example, in vaccines, provide advantageous improvements in inducing immune responses (e.g., antibody responses). For example, for vaccination, stimulating a large (i.e., strong) production of antibodies is beneficial. Strong antibody production indicates a robust immune response, which is essential for the effective neutralization of pathogens. Sufficient antibody levels, over an extended period, confer enhanced protection against the targeted infectious agent, providing sustained defense and reducing the likelihood of infection and subsequent disease. Strong antibody responses can play a crucial role in preventing outbreaks of existing or novel infectious diseases. By minimizing susceptible individuals, high levels of immunity within a community act as a barrier to pathogen transmission, thereby reducing the likelihood of outbreaks and epidemics.

[0016] However, vaccines using lipid nanoparticles as antigen carriers have been shown to struggle to elicit high antibody responses in vaccinated individuals. In some cases, lipid nanoparticles may trigger immune tolerance, where the immune system becomes less sensitive to vaccine antigens. This can hinder the production of a robust antibody response because the immune system cannot adequately respond to the vaccine components. Furthermore, the size and structure of lipid nanoparticles may affect their ability to deliver vaccine antigens to antigen-presenting cells, thereby limiting the production of antibody-producing immune cells. Additionally, lipid nanoparticles can potentially modulate the immune response in ways that may be detrimental to high antibody levels. For example, certain lipid components or adjuvants used in lipid nanoparticle formulations may bias the immune response towards less antibody-centric characteristics, leading to reduced antibody production.

[0017] The materials and methods disclosed herein overcome these difficulties by using specific lipid nanoparticle compositions that have been shown herein to be surprisingly effective in inducing high levels of antibody production. These provided lipid nanoparticle formulations comprise selected materials combined in relative amounts with specific relationships to each other. Notably, the importance of these relative amounts and the specific relationships between them, particularly regarding their beneficial effects on stimulating enhanced immune responses, have not been previously recognized.

[0018] B. Definition

[0019] Unless otherwise expressly indicated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Furthermore, any methods or materials similar to or equivalent to those described herein may be used in practice with this disclosure. For the purposes of this disclosure, the following terms are defined.

[0020] The abbreviations used herein have their conventional meanings in the fields of chemistry and biology. The description of the compounds disclosed herein is subject to the principles of chemical bonding known to those skilled in the art. Therefore, where a group can be substituted by one or more of a plurality of substituents, such substitutions are chosen to conform to the principles of chemical bonding and to yield compounds that are not inherently unstable and / or, as known to those skilled in the art, may be unstable under environmental conditions (e.g., aqueous, neutral, or physiological conditions). When a substituent is specified by its conventional chemical formula (written from left to right), it equally encompasses chemically identical substituents produced when the structure is written from right to left; for example, -CH2O- is equivalent to -OCH2-.

[0021] Unless otherwise stated, the compounds disclosed herein may also contain atomic isotopes in non-natural proportions on one or more atoms constituting such compounds. For example, the compounds may use isotopes such as deuterium (… 2H), tritium ( 3 H), Iodine-125 ( 125 I), carbon-13 ( 13 C) or carbon-14 ( 14 C) Marking. All isotopic variations of the compounds disclosed herein, whether radioactive or non-radioactive, are covered within the scope of this disclosure.

[0022] As used herein, when referring to chemical substances, the term "substitution" means replacing a hydrogen atom with a non-hydrogen atom or a group of covalently bonded atoms. The atom or group of atoms that replaces the hydrogen atom is called a "substituent".

[0023] As used herein, when referring to chemical substances, the term "member" refers to a non-hydrogen atom in a covalently bonded group of atoms, such as a compound or its substituents.

[0024] As used herein, unless the context clearly states otherwise, the singular form "a / an" and "described" include plural indicators. Thus, for example, references to "phospholipids" optionally include combinations of two or more phospholipids, etc.

[0025] As used herein, the terms “about” and “approximately” when used to modify a quantity specified as a numerical value or range indicate that the numerical value and a reasonable deviation from a value known to those skilled in the art, such as ±20%, ±10%, or ±5%, are within the intended meaning of the value.

[0026] As used herein, the term “and / or” means and covers any and all possible combinations of one or more of the associated listed items, as well as the absence of such combinations when interpreted in an alternative context (“or”).

[0027] As used herein, the terms “including,” “comprising,” “having,” “containing,” and their variations are inclusive and open-ended, and do not exclude additional, unlisted elements or method steps besides those expressly enumerated. As used herein, the phrase “consisting of” is closed-ended and excludes any element, step, or component not expressly specified. As used herein, the phrase “generally constitutes” limits the scope of the described feature to the specified materials or steps, and those materials or steps that do not materially affect the essential and novel characteristics of the disclosed feature.

[0028] The terms “optional” or “optionally” mean that the event, situation or substituent described below may or may not occur, and the description includes instances where the event or situation occurs and instances where the event or situation does not occur.

[0029] When used in this document to refer to an element or characteristic, the terms “first,” “second,” “third,” etc., are used only to more clearly distinguish or identify multiple elements or characteristics and are not intended to indicate an order or other sequence or numerical limitation, or to require the presence of each of the multiple elements or characteristics.

[0030] As used herein, the terms "lipid particle," "lipid nanoparticle," and "LNP" refer to particles comprising phospholipids and ionizable lipids. Lipid particles may contain additional lipid components, such as sterols and / or conjugated lipids, and may further contain nucleic acids, wherein the nucleic acids may be encapsulated within the particles. Lipid particles and methods for their preparation are disclosed, for example, in U.S. Patent Application Publications Nos. 2004 / 0142025 and 2007 / 0042031 and International Patent Application Publication No. WO2012 / 000104.

[0031] As used herein, the term "phospholipid" refers to a class of lipids having a hydrophilic "headgroup" containing a phosphate ester and a hydrophobic portion. The hydrophobic portion may contain one or more hydrophobic groups, most typically two. The hydrophobic groups are also called hydrophobic "tails" and may be derived from fatty acids and linked by alcohol residues (e.g., glycerol). Exemplary structures of phospholipids include phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, phosphatidylcholine, lysophosphatidylcholine, and lysophosphatidylethanolamine.

[0032] As used herein, the term "ionizable lipid" refers to a type of lipid that carries a net positive charge at a selected pH (e.g., acidic or physiological pH). In some cases, ionizable lipids include ionizable primary, secondary, or tertiary amine head groups (e.g., pH-titrile). In some cases, ionizable lipids promote the encapsulation of negatively charged nucleic acid (e.g., mRNA or siRNA) payloads during particle formation. In some cases, ionizable lipids promote endosome fusion and cytoplasmic release of the payload after cellular uptake of lipid nanoparticles.

[0033] As used herein, the terms “permanently charged lipids,” “permanently charged cationic lipids,” and “permanently charged ionic lipids” generally refer to lipid species that carry a net positive charge regardless of the pH of their biological environment.

[0034] As used herein, the term "conjugated lipid" refers to polymer-conjugated lipids, such as polymer-conjugated lipids that inhibit lipid particle aggregation. Such lipid conjugates include, but are not limited to, polyamide oligomers (e.g., ATTA-lipid conjugates), polysarcosine-lipid conjugates, polyoxazoline (POZ)-lipid conjugates, PEG-lipid conjugates such as PEG coupled with dialkoxypropyl, PEG coupled with diacylglycerol, PEG coupled with cholesterol, PEG coupled with phosphatidylethanolamine, PEG coupled with ceramide (see, for example, U.S. Patent No. 5,885,613, the disclosure of which is incorporated herein by reference in its entirety for all purposes), cationic PEG lipids, and mixtures thereof. PEG can be conjugated directly to lipids or linked to lipids via a linker portion. Any linker portion suitable for coupling polymers to lipids can be used, including, for example, ester-free linker portions and ester-containing linker portions.

[0035] As used herein, the term "salt" refers to the acid salt or base salt of the compounds disclosed herein. A "pharmaceutically acceptable salt" is a salt that is compatible with other components of a formulation containing the compound and is harmless to its recipient (i.e., the subject). Therefore, it should be understood that pharmaceutically acceptable salts do not cause significant adverse toxicological effects on the subject.

[0036] As used herein, the term "nucleic acid" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in single-stranded or double-stranded form and polymers thereof. Unless specifically defined, the term encompasses nucleic acids containing nucleotide analogs or modified backbone residues or bonds that are synthetic, naturally occurring, or unnatural, and that have binding properties similar to and are metabolized in a similar manner to reference nucleotides. Non-limiting examples of nucleotide analogs are described, for example, in International Patent Application No. WO 2007 / 024708. Examples of nucleic acids including such nucleotide analogs, modified backbone residues, or bonds include, but are not limited to, nucleic acids containing phosphate thioesters, aminophosphate esters, methylphosphonates, chiral methylphosphonates, 2'-O-methylribonucleotides, and peptide nucleic acids (PNAs). Unless otherwise stated, a particular nucleic acid sequence also implicitly encompasses its conserved variants (e.g., degenerate codon substitutions), alleles, orthologs, single nucleotide polymorphisms (SNPs), complementary sequences, and explicitly indicated sequences. Specifically, degenerate codon substitution can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with a mixture of bases and / or deoxyinosine (Batzer et al., (191) Nucleic Acid Res. 19:5081; Ohtsuka et al., (1985) Journal of Biol. Chem. 260:2605; and Rossolini et al., (1994) Mol. Cell. Probes 8:91).

[0037] Non-limiting examples of polynucleotides or nucleic acids include DNA, RNA, coding or non-coding regions of genes or gene segments, intergenic DNA, loci (locus) as defined by linkage analysis, exons, introns, messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA), short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), small nucleolar RNA (snoRNA), ribozymes, deoxynucleotides (dNTPs), or dideoxynucleotides (ddNTPs). Polynucleotides may also include complementary DNA (cDNA), which is the DNA representation of mRNA, typically obtained by reverse transcription of messenger RNA (mRNA) or by amplification. Polynucleotides may also include DNA molecules produced synthetically or by amplification, genomic DNA (gDNA), recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, or primers. Polynucleotides may contain modified nucleotides, such as methylated nucleotides, nucleotide analogs, and / or nucleosides suitable for reducing the immunogenicity of RNA, as described in International Patent Application No. WO 2007 / 024708. If present, modifications to the nucleotide structure may be imparted before or after polymer assembly. The nucleotide sequence may be interspersed with non-nucleotide components. Polynucleotides may be further modified post-polymerization, such as by binding to labeled components. Unless otherwise specified, when provided, polynucleotide sequences are listed in a 5' to 3' orientation.

[0038] Nucleic acids or polynucleotides can be double-stranded or triple-stranded nucleic acids, as well as single-stranded molecules. In double-stranded or triple-stranded nucleic acids, the nucleic acid strands do not need to be homoelongated; for example, double-stranded nucleic acids do not need to be double-stranded along the entire length of both strands.

[0039] Nucleic acid modification can include the addition of chemical groups that incorporate additional charges, polarizations, hydrogen bonds, electrostatic interactions, and functionalities into individual nucleic acid bases or as a whole nucleic acid. Such modifications include base modifications such as 2'-sugar modifications, 5-pyrimidine modifications, 8-purine modifications, modifications at the amine site outside the cytosine ring, substitution of S-bromouracil, backbone modifications, and uncommon base pairing combinations such as isobasic cytosine and isoguanidine.

[0040] Nucleic acids can be derived from fully chemically synthesized methods, such as solid-phase mediated chemical synthesis, from biological sources, such as by isolation from any species that produces nucleic acids, or from methods involving manipulation of nucleic acids using molecular biological tools, such as DNA replication, PCR amplification, reverse transcription, in vitro transcription, as described, for example, in International Patent Application Publication No. WO 2007 / 024708, or from combinations of these methods.

[0041] As used herein in the context of lipid nanoparticles and nucleic acids, the term "fully encapsulated" means that the nucleic acids in the particles do not significantly degrade upon exposure to serum or upon nuclease assays that would significantly degrade free nucleic acids. In a fully encapsulated system, preferably less than 25% of the particle nucleic acids are degraded in treatments that typically degrade 100% of free nucleic acids, more preferably less than 10%, and most preferably less than 5%. Full encapsulation also indicates that the particles are serum-stable, i.e., they do not rapidly disintegrate into their component parts upon administration in vivo.

[0042] As used herein, the term "vaccine" refers to a composition comprising at least one antigen or immunogen or comprising a nucleic acid molecule encoding at least one antigen or immunogen, optionally in a pharmaceutically acceptable carrier or lipid particle, wherein the composition may be used to induce an immune response against the antigen or immunogen in a subject to enhance the subject's immunity to disease and / or infection.

[0043] As used herein, the term "subject" refers to a vertebrate, and preferably a mammal. Mammal subjects to whom the provided compositions are suitable include, but are not limited to, mice, rats, apes, humans, farm animals, sporting animals, and pets. In some embodiments, the subject is a human. In some embodiments, the subject is male. In some embodiments, the subject is female. In some embodiments, the subject is an adult. In some embodiments, the subject is an adolescent. In some embodiments, the subject is a child. In some embodiments, the subject is 10 years of age or older, for example, 20 years of age or older, 30 years of age or older, 40 years of age or older, 50 years of age or older, 60 years of age or older, 70 years of age or older, or 80 years of age or older. In some embodiments, the subject is less than 80 years of age, for example, less than 70 years of age, less than 60 years of age, less than 50 years of age, less than 40 years of age, less than 30 years of age, less than 20 years of age, or less than 10 years of age.

[0044] As used herein, the terms "pharmaceuticalally acceptable excipient" and "pharmaceuticalally acceptable carrier" refer to substances that facilitate administration of the active agent to a subject and facilitate absorption by the subject, and that such substances may be included in the compositions of this disclosure without causing significant adverse toxicological effects on the subject. Non-limiting examples of pharmaceutically acceptable excipients and carriers include water, NaCl, physiological saline solutions, standard sucrose, standard glucose, binders, fillers, disintegrants, lubricants, coatings, etc. Those skilled in the art will recognize that other pharmaceutically acceptable excipients and carriers are useful in this disclosure.

[0045] As used herein, the term “administration” refers to oral administration to a subject, as a suppository, local contact, parenteral administration, intravenous administration, intraperitoneal administration, intramuscular administration, intralesional administration, intranasal administration, subcutaneous administration, intrathecal administration, intraparenchymal administration, subretinal administration, or intravitreal administration, or implantation of a sustained-release device, such as a microosmotic pump.

[0046] As used herein, the term “therapeutic effective amount” means the amount or dose of a compound, composition, or formulation administered to produce a therapeutic effect. The exact amount or dose will depend on the purpose of treatment and will be determined by a person skilled in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (Vols. 1–3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 23rd edition (2020), edited by Gennaro, Lippincott, Williams & Wilkins).

[0047] As used herein, the term "treatment" refers to any procedure that achieves any sign of success in eliminating or improving an injury, pathology, symptom, or condition (e.g., pain), including any objective or subjective parameters such as the reduction, relief, or decrease of symptoms, or making the symptoms, injury, pathology, or condition more tolerable for the patient; reducing the frequency or duration of symptoms or conditions; or, in some cases, preventing the onset of one or more symptoms. Treatment or improvement of symptoms can be based on any objective or subjective parameters, including, for example, the results of a physical examination or laboratory test.

[0048] C. Lipid nanoparticles and vaccines

[0049] On the one hand, this disclosure provides various lipid nanoparticles, and vaccines including the provided lipid nanoparticles. Lipid nanoparticles typically comprise conjugated lipids, phospholipids or pharmaceutically acceptable salts thereof, ionizable lipids or pharmaceutically acceptable salts thereof, cholesterol or derivatives thereof, and nucleic acids encoding proteins of interest (e.g., antigens or fragments thereof). Specific selection, composition, and amounts (e.g., relative amounts) of these components provide surprising improvements in the ability of lipid nanoparticles and vaccines to induce immune responses (e.g., immune responses characterized by high levels of antibody production). For example, lipid nanoparticles and vaccines have been shown herein to induce strong immune responses when: (1) the phospholipids are phospholipids with a net neutral charge (e.g., a net neutral charge at physiological pH); (2) the concentration of conjugated lipids in the lipid nanoparticles is below a certain threshold (e.g., less than 1 mol% of the total lipids in the lipid nanoparticles); and (3) the concentration of ionizable lipids or pharmaceutically acceptable salts thereof is above a certain threshold as a function of the conjugated lipid concentration (e.g., greater than 51.1-5.7X + 8.0X of the total lipids in the lipid nanoparticles). 2 (3) mol%, where X is the total lipids of the lipid nanoparticles in mol%, and / or (4) the concentration of cholesterol or its derivatives in the lipid nanoparticles is below a certain threshold as a function of the concentration of conjugated lipids (e.g., less than 39.3 + 2.3X - 5.6X of the total lipids of the lipid nanoparticles). 2 mol%, where X is the total lipid content of the lipid nanoparticles (mol%).

[0050] In some examples of the lipid nanoparticles and vaccines provided, conjugated lipids in the lipid nanoparticles account for about 0.6 mol% to about 1 mol% of the total lipids of the lipid nanoparticles (e.g., about 0.6 mol% to about 0.9 mol%, about 0.6 mol% to about 0.8 mol%, about 0.6 mol% to 0.7 mol%, about 0.7 mol% to about 1 mol%, about 0.7 mol% to about 0.9 mol%, about 0.7 mol% to about 0.8 mol%, about 0.8 mol% to about 1 mol%, or about 0.8 mol% to about 0.9 mol%, or about 0.9 mol% to about 1 mol%), and phospholipids or pharmaceutically acceptable salts thereof account for about 8.5 mol% to about 11.5 mol% of the total lipids of the lipid nanoparticles (e.g., about 8.5 mol% to about 10.75 mol%, about 8.5 mol% to about 10 mol%, about 8.5 mol% to about 9.25 mol%). From about 11.5 mol%, about 9.25 mol%, about 10.75 mol%, about 9.25 mol%, about 10 mol%, about 10 mol%, about 11.5 mol%, about 10 mol%, about 10.75 mol%, or about 10.75 mol%, to about 11 mol%, ionizable lipids or their pharmaceutically acceptable salts comprise 50.5 mol% to 58.5 mol% of the total lipids in the lipid nanoparticles (e.g., about 50.5 mol% to about 56.5 mol%, about 50.5 mol% to about 54.5 mol%, about 50.5 mol% to about 52.5 mol%, about 52.5 mol% to about 58.5 mol%, about 52.5 mol% to about 56.5 mol%, about 52.5 mol% to about 54.5 mol%, about 54.5 mol% to about 58.5 mol%, about 54.5 mol%, about 54.5 mol%, about 54.5 mol%, about 56.5 mol%. (e.g., about 29 mol% or about 56.5 mol% to 58.5 mol%), and cholesterol or its derivatives account for 29 mol% to 36 mol% of the total lipids in the lipid nanoparticles (e.g., about 29 mol% to about 34.25 mol%, about 29 mol% to about 32.5 mol%, about 29 mol% to about 30.75 mol%, about 30.75 mol% to about 36 mol%, about 30.75 mol% to about 34.25 mol%, about 30.75 mol% to 32.5 mol%, about 32.5 mol% to about 36 mol%, about 32.5 mol% to about 34.25 mol%, or about 34.25 mol% to about 36 mol%).

[0051] In other examples of the lipid nanoparticles and vaccines provided, the conjugated lipids in the lipid nanoparticles account for about 0.1 mol% to about 0.6 mol% of the total lipids of the lipid nanoparticles (e.g., about 0.1 mol% to about 0.475 mol%, about 0.1 mol% to about 0.35 mol%, about 0.1 mol% to about 0.225 mol%, about 0.225 mol% to about 6 mol%, about 0.225 mol% to about 0.475 mol%, about 0.225 mol% to about 0.35 mol%, about 0.35 mol% to about 0.6 mol%, about 0.35 mol% to about 0.475 mol%, or about 0.475 mol% to about 0.6 mol%), and phospholipids or pharmaceutically acceptable salts thereof account for about 8.5 mol% to about 11.5 mol% of the total lipids of the lipid nanoparticles (e.g., about 8.5 mol% to about 10.75 mol%). The lipid nanoparticles contain 53.5 mol% to 61.5 mol% of total lipids, ranging from about 8.5 mol% to about 9.25 mol%, about 9.25 mol% to about 11.5 mol%, about 9.25 mol% to about 10.75 mol%, about 9.25 mol% to about 10 mol%, about 10 mol% to about 11.5 mol%, about 10 mol% to about 10.75 mol%, or about 10.75 mol% to about 11 mol%, of ionizable lipids or their pharmaceutically acceptable salts, comprising 53.5 mol% to 61.5 mol% of total lipids (e.g., about 53.5 mol% to about 59.5 mol%, about 53.5 mol% to about 57.5 mol%, about 53.5 mol% to about 55.5 mol%, about 55.5 mol% to about 61.5 mol%, about 55.5 mol% to about 59.5 mol%, about 55.5 mol% to about 57.5 mol%. (e.g., about 57.5 mol% to about 61.5 mol%, about 57.5 mol% to about 59.5 mol%, or about 59.5 mol% to 61.5 mol%), and cholesterol or its derivatives account for 32 mol% to 39 mol% of the total lipids in the lipid nanoparticles (e.g., about 32 mol% to about 37.25 mol%, about 32 mol% to about 35.5 mol%, about 32 mol% to about 33.75 mol%, about 33.75 mol% to about 39 mol%, about 33.75 mol% to about 37.25 mol%, about 33.75 mol% to about 35.5 mol%, about 35.5 mol% to about 39 mol%, about 35.5 mol% to about 37.25 mol%, or about 37.25 mol% to about 39 mol%).

[0052] In some instances, the provided lipid nanoparticles may further comprise permanently charged cationic lipids. The lipid nanoparticles may include permanently charged cationic lipids comprising, for example, from about 1 mol% to 10 mol% of the total lipids in the lipid nanoparticles, such as from about 1 mol% to about 5.6 mol%, from about 1 mol% to about 3.2 mol%, from about 1 mol% to about 1.8 mol%, from about 1.8 mol% to about 10 mol%, from about 1.8 mol% to about 5.6 mol%, from about 1.8 mol% to about 3.2 mol%, from about 3.2 mol% to about 10 mol%, or from about 3.2 mol% to 5.6 mol% or from about 5.6 mol% to about 10 mol%. With respect to the upper limit, permanently charged cationic lipids may constitute, for example, no more than about 10 mol% of the total lipids in the lipid nanoparticles, for example, no more than about 6.8 mol%, no more than about 4.6 mol%, no more than about 3.2 mol%, no more than about 2.2 mol%, no more than about 1.5 mol%, or no more than about 1 mol%. With respect to the lower limit, permanently charged cationic lipids may constitute, for example, no less than about 1 mol% of the total lipids in the lipid nanoparticles, for example, no less than about 1.5 mol%, no less than about 2.2 mol%, no less than about 3.2 mol%, no less than about 4.6 mol%, or no less than about 6.8 mol%. In some instances, the lipid nanoparticles provided do not include permanently charged cationic lipids.

[0053] The properties and relative amounts of the lipid nanoparticle components can also be selected to provide lipid nanoparticles with a pKa favorable for use in vaccines. For example, in some embodiments, the pKa of the lipid nanoparticles is about 5.8 to about 6.9, such as about 5.8 to about 6.8, about 5.8 to about 6.7, about 5.8 to about 6.6, about 5.8 to about 6.5, about 5.8 to about 6.4, about 5.8 to about 6.3, about 5.8 to about 6.2, about 5.8 to about 6.1, about 5.8 to about 6.0, about 5.8 to about 5.9, about 5.9 to about 6.9, about 5.9 to about 6.8, about 5.9 to about 6.7, about 5... 0.9 to about 6.6, about 5.9 to about 6.5, about 5.9 to about 6.4, about 5.9 to about 6.3, about 5.9 to about 6.2, about 5.9 to about 6.1, about 5.9 to about 6.0, about 6.0 to about 6.9, about 6.0 to about 6.8, about 6.0 to about 6.7, about 6.0 to about 6.6, about 6.0 to about 6.5, about 6.0 to about 6.4, about 6.0 to about 6.3, about 6.0 to about 6.2, about 6.0 to about 6.1, about 6.1 to about 6.9, About 6.1 to about 6.8, about 6.1 to about 6.7, about 6.1 to about 6.6, about 6.1 to about 6.5, about 6.1 to about 6.4, about 6.1 to about 6.3, about 6.1 to about 6.2, about 6.2 to about 6.9, about 6.2 to about 6.8, about 6.2 to about 6.7, about 6.2 to about 6.6, about 6.2 to about 6.5, about 6.2 to about 6.4, about 6.2 to about 6.3, about 6.3 to about 6.9, about 6.3 to about 6.8, about 6.3 to about 6. 7. about 6.3 to about 6.6, about 6.3 to about 6.5, about 6.3 to about 6.4, about 6.4 to about 6.9, about 6.4 to about 6.4 to about 6.8, about 6.4 to about 6.7, about 6.4 to about 6.6, about 6.4 to about 6.5, about 6.5 to about 6.9, about 6.5 to about 6.8, about 6.5 to about 6.6, about 6.6 to about 6.9, about 6.6 to about 6.8, about 6.6 to about 6.7, about 6.7 to about 6.8 or about 6.8 to about 6.9.

[0054] The properties and relative amounts of the lipid nanoparticle components can also be selected to provide lipid nanoparticles whose size is beneficial for use in vaccines. The average diameter of the lipid nanoparticles can be, for example, about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 60 nm to about 100 nm, about 50 nm to about 80 nm, about 60 nm to about 80 nm, about 60 nm to about 90 nm, or about 70 nm to about 90 nm.

[0055] The provided lipid nanoparticles can be further configured to be substantially non-toxic, for example, by selecting their components. When the lipid nanoparticles are used in a vaccine, the vaccine may additionally include pharmaceutically acceptable excipients.

[0056] 1. Conjugated lipids

[0057] The lipid nanoparticles disclosed herein typically include at least one conjugated lipid. The conjugated lipids can be selected or designed to provide improved performance in inducing desired immune responses, such as increasing the production of antibodies associated with the target antigen, to the lipid nanoparticles or vaccines comprising them. Furthermore, the amount of conjugated lipids present in the lipid nanoparticles has been shown in this disclosure to influence the ability of the lipid nanoparticles to induce a strong immune response. For example, conjugated lipid masses below certain thresholds and optionally above certain other thresholds have proven beneficial in producing lipid nanoparticles that stimulate high levels of antibody production.

[0058] In some instances, when the amount of conjugated lipids in the lipid nanoparticles is less than about 1 mol% of the total lipids in the lipid nanoparticles, the provided lipid nanoparticles and vaccines induce a strong immune response. The conjugated lipids in the provided lipid nanoparticles may account for, for example, from about 0.1 mol% to about 1 mol% of the total lipids in the lipid nanoparticles, for example, from about 0.1 mol% to about 0.56 mol%, from about 0.1 mol% to about 0.32 mol%, from about 0.1 mol% to about 0.18 mol%, from about 0.18 mol% to about 1 mol%, from about 0.18 mol% to about 0.56 mol%, from about 0.18 mol% to about 0.32 mol%, from about 0.32 mol% to about 1 mol%, from about 0.32 mol% to about 0.56 mol%, or from about 0.56 mol% to about 1 mol%.

[0059] In some instances, when the amount of conjugated lipids in the lipid nanoparticles is greater than about 0.5 mol% of the total lipids in the lipid nanoparticles, the provided lipid nanoparticles and vaccines induce a strong immune response. The conjugated lipids may comprise, for example, about 0.5 mol% to about 1 mol% of the total lipids in the lipid nanoparticles, e.g., about 0.5 mol% to about 0.875 mol%, about 0.5 mol% to about 0.75 mol%, about 0.5 mol% to about 0.625 mol%, about 0.625 mol% to about 1 mol%, about 0.625 mol% to about 0.875 mol%, about 0.625 mol% to about 0.75 mol%, about 0.75 mol% to about 1 mol%, or about 0.75 mol% to about 0.875 mol%.

[0060] Regarding the upper limit, the conjugated lipids in the provided lipid nanoparticles may account for, for example, no more than about 1 mol% of the total lipids in the lipid nanoparticles, such as no more than about 0.95 mol%, no more than about 0.9 mol%, no more than about 0.85 mol%, no more than about 0.8 mol%, no more than about 0.75 mol%, no more than about 0.7 mol%, no more than about 0.65 mol%, no more than about 0.6 mol%, no more than about 0.55 mol%, no more than about 0.5 mol%, no more than about 0.45 mol%, no more than about 0.4 mol%, no more than about 0.35 mol%, no more than about 0.3 mol%, no more than about 0.25 mol%, no more than about 0.2 mol%, no more than about 0.15 mol%, or no more than about 0.1 mol%. With regard to the lower limit, the conjugated lipids may account for, for example, not less than about 0.1 mol% of the total lipids in the lipid nanoparticles, such as not less than about 0.15 mol%, not less than about 0.2 mol%, not less than about 0.25 mol%, not less than about 0.3 mol%, not less than about 0.35 mol%, not less than about 0.4 mol%, not less than about 0.45 mol%, not less than about 0.5 mol%, not less than about 0.55 mol%, not less than about 0.6 mol%, not less than about 0.65 mol%, not less than about 0.7 mol%, not less than about 0.75 mol%, not less than about 0.8 mol%, not less than about 0.85 mol%, not less than about 0.9 mol%, or not less than about 0.95 mol%.

[0061] In some embodiments, the lipid nanoparticles comprise one type of conjugated lipid. In other embodiments, the lipid nanoparticles comprise two or more types of conjugated lipids, for example, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more types of conjugated lipids. One or more conjugated lipids may be independently selected or configured to control particle size during formation and / or to prevent particle aggregation by spatially stabilizing the lipid nanoparticles. The conjugated lipids in the lipid nanoparticles may be located at the surface of the particles, wherein the hydrophilic polymer of the conjugated lipids is outwardly oriented and binds to an aqueous environment, and the lipid components of the conjugated lipids are embedded in the particles to anchor them in place.

[0062] Suitable conjugated lipids for use with the provided lipid nanoparticles include, but are not limited to, polyethylene glycol (PEG)-lipid conjugations, ATTA-lipid conjugations, cationic polymer-lipid conjugations (CPL), polyoxazoline (POZ)-lipids, polysarcosine (pSAR)-lipids, and mixtures thereof. In some embodiments, the lipid nanoparticles comprise PEG-lipid conjugations or ATTA-lipid conjugations, optionally together with CPL.

[0063] In a preferred embodiment, the conjugated lipid comprises or is composed of PEG-lipids. Examples of PEG-lipids include, but are not limited to, PEG coupled with a dialkoxypropyl group (PEG-DAA) (as described, for example, in International Patent Application Publication No. WO 05 / 026372), PEG coupled with a diacylglycerol (PEG-DAG) (as described, for example, in U.S. Patent Application Publications Nos. 2003 / 0077829 and 2005 / 0008689), PEG coupled with a phospholipid such as phosphatidylethanolamine (PEG-PE), PEG coupled with a ceramide (as described, for example, in U.S. Patent No. 5,885,613), PEG coupled with cholesterol or a derivative thereof, mPEG(2000)-N,N-bistetradecylacetamide (ALC-0159), mPEG(2000)-stearate, 1,2-dimyristoyl-rac-glycerol-3-methoxypolyethylene glycol-2000 (DMG-PEG). The PEG-C-DOMG, R-3-[(ω-methoxy-poly(ethylene glycol)2000)carbamoyl)]-1,2-dimyristyloxypropyl-3-amine, and mixtures thereof are all of the PEG lipids described in International Patent Application Publication No. WO 2022 / 133344. The disclosures of these patent documents are incorporated herein by reference in their entirety for all purposes. The lipid nanoparticles provided may comprise one or more methyl-terminated PEG-lipids, one or more unterminated PEG-lipids, or combinations thereof.

[0064] PEG is a linear, water-soluble polymer of repeating ethylene glycol units. PEG is classified according to its molecular weight; for example, PEG 2000 has an average molecular weight of about 2,000 Daltons, and PEG 5000 has an average molecular weight of about 5,000 Daltons. Due to its polydispersity, these molecular weights are average molecular weights. PEG is commercially available from Sigma Chemical Co. and other companies, and includes, for example, the following: monomethoxy polyethylene glycol (MePEG-OH), monomethoxy polyethylene glycol-succinate (MePEG-S), monomethoxy polyethylene glycol succinimide succinate (MePEG-S-NHS), monomethoxy polyethylene glycol-amine (MePEG-NH2), monomethoxy polyethylene glycol-trifluoroethyl sulfonate (MePEG-TRES), and monomethoxy polyethylene glycol-imidazolyl-carbonyl (MePEG-IM). Other PEGs, such as those described in U.S. Patents 6,774,180 and 7,053,150 (e.g., mPEG (20 kDa)amine), can also be used to prepare the PEG-lipid conjugates disclosed herein. The disclosures of these patents are incorporated herein by reference in their entirety for all purposes. Additionally, monomethoxy polyethylene glycol acetic acid (MePEG-CH2COOH) is particularly useful for preparing PEG-lipid conjugates, including, for example, PEG-DAA conjugates.

[0065] The PEG moiety of the PEG-lipid conjugate described herein may contain an average molecular weight in the range of about 550 Daltons to about 10,000 Daltons. In some cases, the average molecular weight of the PEG moiety is about 750 Daltons to about 5,000 Daltons (e.g., about 1,000 Daltons to about 5,000 Daltons, about 1,500 Daltons to about 3,000 Daltons, about 750 Daltons to about 3,000 Daltons, about 750 Daltons to about 2,000 Daltons, etc.). In preferred embodiments, the average molecular weight of the PEG moiety is about 2,000 Daltons or about 750 Daltons.

[0066] In some cases, PEG may optionally be substituted with alkyl, alkoxy, acyl, or aryl groups. PEG may be directly conjugated to lipids or linked to lipids via a linker motif. Any linker motif suitable for coupling PEG to lipids may be used, including, for example, ester-free linker motifs and ester-containing linker motifs. In a preferred embodiment, the linker motif is an ester-free linker motif. As used herein, the term "ester-free linker motif" refers to a linker motif that does not contain a carboxylic acid ester bond (-OC(O)-). Suitable ester-free linker motifs include, but are not limited to, amide (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), urethane (NHC(O)O-), urea (-NHC(O)NH-), disulfide (-SS-), ether (-O-), succinyl ((O)CCH2CH2C(O)-), succinimide (-NHC(O)CH2CH2C(O)NH-), and combinations thereof (such as linkers containing both urethane and amide linker motifs). In a preferred embodiment, a urethane linker is used to couple PEG to lipids.

[0067] In other embodiments, the ester-containing linker portion is used to couple PEG to the lipid. Suitable ester-containing linker portions include, for example, carbonates (-OC(O)O-), succinyl groups, phosphate esters (-O-(O)POH-O-), sulfonates, and combinations thereof.

[0068] In addition to the foregoing, it will be apparent to those skilled in the art that other hydrophilic polymers can be used instead of PEG. Examples of suitable polymers that can be used to replace PEG include, but are not limited to, ATTA, cationic polymers, polyoxazoline (POZ), polysarcosine, polyvinylpyrrolidone, polymethyloxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide and polydimethylacrylamide, polylactic acid, polyglycolic acid, poly(ethyl ethylene phosphate) (PEEP), and derivatized cellulose (such as hydroxymethyl cellulose or hydroxyethyl cellulose).

[0069] The conjugated lipids of the provided lipid nanoparticles may include, for example, one or more of, or consist of, the following: polyethylene glycol (PEG)-lipid conjugates, polyamide (ATTA)-lipid conjugates, or mixtures thereof. In a preferred embodiment, the nucleic acid-lipid particles comprise PEG-lipid conjugates or ATTA-lipid conjugates. The conjugated lipids may comprise PEG-lipids, including, for example, PEG-diacylglycerol (DAG), PEG-dialkoxypropyl (DAA), PEG-phospholipids, PEG-ceramide (Cer), or mixtures thereof. The PEG-DAA conjugate may be PEG-dilauryloxypropyl (C12), PEG-dimyristyloxypropyl (C14), PEG-dispalmityloxypropyl (C16), PEG-distearateloxypropyl (C18), or mixtures thereof.

[0070] Other PEG-lipid conjugates suitable for use in the provided lipid nanoparticles include, but are not limited to, mPEG2000-1,2-di-O-alkyl-sn3-carbamoylglycerol ester (PEG-C-DOMG). The synthesis of PEG-C-DOMG is described in PCT application No. PCT / US08 / 88676, filed December 31, 2008, the disclosure of which is incorporated herein by reference in its entirety for all purposes. Other PEG-lipid conjugates suitable for use in this disclosure include, but are not limited to, 1-[8'-(1,2-dimyristoyl-3-propoxy)-formamido-3',6'-dioxaoctyl]carbamoyl-w-methylpoly(ethylene glycol) (2KPEG-DMG). The synthesis of 2KPEG-DMG is described in U.S. Patent No. 7,404,969, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0071] In some instances, the provided lipid nanoparticles and vaccines comprising lipid nanoparticles have exhibited the ability to induce strong immune responses, in part because the conjugated lipids in the lipid nanoparticles are lipids having two or more terminal hydrocarbon chains (e.g., terminal alkyl chains or terminal alkenyl chains), each terminal hydrocarbon chain having five or more members, and each terminal hydrocarbon chain not being directly bonded to an ester. Lipid nanoparticles comprising conjugated lipids having such hydrophobic tails have been shown herein to advantageously stimulate high antibody yields. Conjugated lipids may comprise, for example, N-[(methoxypoly(ethylene glycol))carbamoyl]-1,2-dimyristyloxypropylamine (PEG-c-DMA) or be composed thereof.

[0072] The terminal hydrocarbon chains, such as alkyl chains, of the conjugated lipids in lipid nanoparticles are not particularly limited in length. Each terminal hydrocarbon chain of the conjugated lipid can independently have a length of, for example, C12, C14, C16, C18, C20, C22, or C24. In some instances, the conjugated lipids comprise one or two terminal hydrocarbon chains, each independently being C12, C14, C16, or C18.

[0073] By controlling the composition and concentration of the conjugated lipids in the provided lipid nanoparticles, the rate of exchange of the conjugated lipids from the lipid nanoparticles can be controlled, and consequently, the rate at which the lipid nanoparticles become fusion-promoting. For example, when a PEG-phosphatidylethanolamine conjugate or a PEG-ceramide conjugate is used as the conjugated lipid, the rate at which the lipid nanoparticles become fusion-promoting can be altered, for example, by changing the concentration of the lipid conjugate, by changing the molecular weight of the PEG, or by changing the chain length and saturation of the acyl chain groups on the phosphatidylethanolamine or ceramide. Additionally, other variables, including, for example, pH, temperature, ionic strength, etc., can be used to alter and / or control the rate at which the lipid nanoparticles become fusion-promoting. Other methods that can be used to control the rate at which lipid nanoparticles become fusion-promoting will become apparent to those skilled in the art upon reading this disclosure.

[0074] 2. Ionizable lipids

[0075] The lipid nanoparticles disclosed herein typically comprise at least one ionizable lipid or a pharmaceutically acceptable salt thereof. The ionizable lipid can be selected or engineered to provide improved performance in inducing desired immune responses, such as increased production of antibodies associated with the target antigen, to the lipid nanoparticles or vaccines comprising them. Furthermore, the amount of ionizable lipid present in the lipid nanoparticles has been shown in this disclosure to influence the ability of the lipid nanoparticles to induce a strong immune response. For example, a mass of ionizable lipid greater than certain thresholds has been shown to beneficially produce lipid nanoparticles that stimulate high levels of antibody production.

[0076] Furthermore, this disclosure reveals that not only the absolute amount of ionizable lipids in lipid nanoparticles, but also the relative amount of ionizable lipids with respect to conjugated lipids in the lipid nanoparticles, can enhance the immune response induced by lipid nanoparticles. This previously unrecognized specific relationship between the concentrations of ionizable lipids and conjugated lipids can be expressed as a function of these two concentrations. This function can define a threshold criterion such that lipid nanoparticles comprising ionizable lipids at molar concentrations greater than the threshold induce a stronger immune response, wherein the threshold is calculated as a function of the conjugated lipid concentration of the lipid nanoparticles. This function can be expressed, for example, by the equation Y ≥ 51.1 - 5.7X + 8.0X. 2Let X be defined as the percentage of conjugated lipids in the total lipids of the lipid nanoparticle, and Y, calculated as a function of X, be the threshold percentage of ionizable lipids or their pharmaceutically acceptable salts in the total lipids of the nanoparticle.

[0077] In some instances, conjugated lipids comprise 1 mol% of the total lipids in the lipid nanoparticles, and ionizable lipids or pharmaceutically acceptable salts thereof comprise at least 53.4 mol% of the total lipids in the lipid nanoparticles. The lipid nanoparticles may include, for example, 0.9 mol% conjugated lipids and at least 52.45 mol% ionizable lipids or pharmaceutically acceptable salts thereof. The lipid nanoparticles may include, for example, 0.8 mol% conjugated lipids and at least 51.66 mol% ionizable lipids or pharmaceutically acceptable salts thereof. The lipid nanoparticles may include, for example, 0.7 mol% conjugated lipids and at least 51.03 mol% ionizable lipids or pharmaceutically acceptable salts thereof. The lipid nanoparticles may include, for example, 0.6 mol% conjugated lipids and at least 50.56 mol% ionizable lipids or pharmaceutically acceptable salts thereof. The lipid nanoparticles may include, for example, 0.5 mol% conjugated lipids and at least 50.25 mol% ionizable lipids or pharmaceutically acceptable salts thereof. Lipid nanoparticles may include, for example, 0.4 mol% conjugated lipids and at least 50.1 mol% ionizable lipids or pharmaceutically acceptable salts thereof. Lipid nanoparticles may include, for example, 0.35 mol% conjugated lipids and at least 50.09 mol% ionizable lipids or pharmaceutically acceptable salts thereof. Lipid nanoparticles may include, for example, 0.3 mol% conjugated lipids and at least 50.11 mol% ionizable lipids or pharmaceutically acceptable salts thereof. Lipid nanoparticles may include, for example, 0.25 mol% conjugated lipids and at least 50.18 mol% ionizable lipids or pharmaceutically acceptable salts thereof. Lipid nanoparticles may include, for example, 0.2 mol% conjugated lipids and at least 50.28 mol% ionizable lipids or pharmaceutically acceptable salts thereof. Lipid nanoparticles may include, for example, 0.15 mol% conjugated lipids and at least 52.43 mol% ionizable lipids or pharmaceutically acceptable salts thereof. Lipid nanoparticles may include, for example, 0.1 mol% of conjugated lipids and at least 50.6 mol% of ionizable lipids or pharmaceutically acceptable salts thereof.

[0078] In some embodiments, the lipid nanoparticles comprise one type of ionizable lipid. In other embodiments, the lipid nanoparticles comprise two or more types of ionizable lipids, such as three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more types of ionizable lipids.

[0079] Ionizable lipids that can be used with the provided lipids include, for example, N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyloxy-N,N-dimethylaminopropane (DODMA), 1,2-distearyloxy-N,N-dimethylaminopropane (DSDMA), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), 3-(N-(N',N'-dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(1, 2-Dimyristyloxypropyl-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), 2,3-dioleoxy-N-[2(spermine-formamido)ethyl]-N,N-dimethyl-1-propylamine trifluoroacetate (DOSPA), bis(octadecylamide-glycyl)spermine (DOGS), 1,2-dilinoleoxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinyloxy-N,N-dimethylaminopropane (DLenDMA), 3-dimethylamino-2-(cholest-5-en-3-β-oxybut-4-oxy)-1-(cis,cis-9,12-octadecadienoxy)propane (CLinDMA), 2-[5'-(cholest-5-en-3.β-...(-oxy)-3'-oxaproloxy)-3-dimethyl-1-(cis,cis-9',1-2'-octadecadienoxy)propane (CpLinDMA), N,N-dimethyl-3,4-dioleoyloxybenzylamine (DMOBA), 1,2-N,N'-dioleoylcarbamoyl-3-dimethylaminopropane (DOcarbDAP), 1,2-N,N'-dilinoleoylcarbamoyl-3-dimethylaminopropane (DLincarbDAP), 1,2-dilinoleoylcarbamoyl-3-dimethylaminopropane (DLinCDAP), 2,2-dilinoleoyl-4-(2-dimethylamino) 2,2-Dilinyl-4-(3-dimethylaminopropyl)-[1,3]-dioxolane (DLin-K-C2-DMA), 2,2-Dilinyl-4-(3-dimethylaminopropyl)-[1,3]-dioxolane (DLin-K-C3-DMA), 2,2-Dilinyl-4-(4-dimethylaminobutyl)-[1,3]-dioxolane (DLin-K-C4-DMA), 2,2-Dilinyl-5-dimethylaminomethyl-[1,3]-dioxane (DLin-K6-DMA), 2,2-Dilinyl-4-N-methylpiperazinyl-[1,3]-dioxolane (DLin-K-MPZ), 2,2-Dilinyl-4-dioxolane Methylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), 1,2-dilinoleoylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-dilinoleoyloxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-dilinoleoyloxy-3-morpholinopropane (DLin-MA), 1,2-dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-dilinoleoylthio-3-dimethylaminopropane (DLin-S-DMA), 1-linoleoyl-2-linoleoyloxy-3-dimethylaminopropane (DLin-2) 1,2-Dilinoleoyl-3-trimethylaminopropane chloride (DLin-TMA.Cl), 1,2-dilinoleoyl-3-trimethylaminopropane chloride (DLin-TAP.Cl), 1,2-dilinoleoyl-3-(N-methylpiperazinyl)propane (DLin-MPZ), 3-(N,N-dilinoleoylamino)-1,2-propanediol (DLinAP), 3-(N,N-dioleoylamino)-1,2-propanediol (DOAP), 1,2-dilinoleoyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), and mixtures thereof.

[0080] In some instances, the provided lipid nanoparticles and vaccines comprising lipid nanoparticles exhibit the ability to induce strong immune responses, in part because the ionizable lipids in the lipid nanoparticles are lipids having three or more terminal hydrocarbon chains (e.g., terminal alkyl chains or terminal alkenyl chains), each terminal hydrocarbon chain having five or more members. For example, the lipid nanoparticles may comprise trialkyl cationic lipids as described in International Patent Application Publication WO 2013 / 126803, ionizable lipids as described in International Patent Application Publication WO 2017 / 049245, or ionizable lipids as described in International Patent Application Publication WO2017 / 075531. Ionizable lipids may comprise, for example, 5-(dimethylamino)valerate (6Z,16Z)-12-((Z)-dec-4-en-1-yl) dodecano-6,16-dien-11-yl ester (3D-P-DMA) or compositions thereof. In other instances, the ionizable lipids are lipids having two terminal hydrocarbon chains. Ionizable lipids may include, for example, 4-(dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-heptadec-6,9,28,31-tetraen-19-yl ester (MC3) or composed thereof.

[0081] 3. Cholesterol

[0082] The lipid nanoparticles disclosed herein typically include sterols, such as cholesterol, or one or more derivatives thereof. Sterols can be selected or designed to provide improved performance in inducing desired immune responses, such as increasing the production of antibodies associated with target antigens, to lipid nanoparticles or vaccines comprising lipid nanoparticles. Furthermore, the amount of sterols present in the lipid nanoparticles has been shown in this disclosure to influence the ability of the lipid nanoparticles to induce strong immune responses. For example, amounts of sterols below certain thresholds have been shown to beneficially produce lipid nanoparticles that stimulate high levels of antibody production.

[0083] Furthermore, this disclosure reveals that not only the absolute amount of cholesterol in lipid nanoparticles, but also the relative amount of cholesterol compared to the conjugated lipids in the lipid nanoparticles, can enhance the immune response induced by lipid nanoparticles. This previously unrecognized specific relationship between cholesterol concentration and conjugated lipid concentration can be expressed as a function of these two concentrations. This function can define a threshold criterion such that lipid nanoparticles containing cholesterol at molar concentrations less than the threshold induce a stronger immune response, wherein the threshold is calculated as a function of the conjugated lipid concentration of the lipid nanoparticles. This function can be expressed, for example, by the formula Z ≤ 39.3 + 2.3X - 5.6X. 2 Let X be the total lipids of the lipid nanoparticles, and Z, calculated as a function of X, be the threshold mol% of cholesterol or its derivatives in the total lipids of the nanoparticles.

[0084] In some instances, conjugated lipids comprise 1 mol% of the total lipids in the lipid nanoparticles, and cholesterol or its derivatives comprise no more than 36 mol% of the total lipids in the lipid nanoparticles. The lipid nanoparticles may include, for example, 0.9 mol% conjugated lipids and no more than 36.83 mol% cholesterol or its derivatives. The lipid nanoparticles may include, for example, 0.8 mol% conjugated lipids and no more than 37.56 mol% cholesterol or its derivatives. The lipid nanoparticles may include, for example, 0.7 mol% conjugated lipids and no more than 38.17 mol% cholesterol or its derivatives. The lipid nanoparticles may include, for example, 0.6 mol% conjugated lipids and no more than 38.67 mol% cholesterol or its derivatives. The lipid nanoparticles may include, for example, 0.5 mol% conjugated lipids and no more than 39.05 mol% cholesterol or its derivatives. The lipid nanoparticles may include, for example, 0.4 mol% conjugated lipids and no more than 39.32 mol% cholesterol or its derivatives. Lipid nanoparticles may include, for example, 0.35 mol% conjugated lipids and no more than 39.42 mol% cholesterol or its derivatives. Lipid nanoparticles may include, for example, 0.3 mol% conjugated lipids and no more than 39.49 mol% cholesterol or its derivatives. Lipid nanoparticles may include, for example, 0.25 mol% conjugated lipids and no more than 39.53 mol% cholesterol or its derivatives. Lipid nanoparticles may include, for example, 0.2 mol% conjugated lipids and no more than 39.54 mol% cholesterol or its derivatives. Lipid nanoparticles may include, for example, 0.15 mol% conjugated lipids and no more than 39.52 mol% cholesterol or its derivatives. Lipid nanoparticles may include, for example, 0.1 mol% conjugated lipids and no more than 39.47 mol% cholesterol or its derivatives.

[0085] In some embodiments, the lipid nanoparticles comprise one type of sterol. In other embodiments, the lipid nanoparticles comprise two or more types of sterols, for example, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more types of ionizable lipids. The lipid nanoparticles may include, for example, cholesterol, cholesterol ketones, cholesterol esters, coprosterol, cholesterol-2'-hydroxyethyl ether, cholesterol-4'-hydroxybutyl ether, cholesterol hydroxyethyl ether, cholesterol hydroxyhexyl ether, cholesterol stearate, cholesterol oleate, 7-β-hydroxycholesterol, 7-α-hydroxycholesterol, 4-β-hydroxycholesterol, cholesterol PEG, β-sitosterol, or any combination thereof. In some instances, the lipid nanoparticles comprise cholesterol, but substantially exclude cholesterol derivatives.

[0086] 4. Phospholipids

[0087] The lipid nanoparticles disclosed herein typically comprise at least one phospholipid or a pharmaceutically acceptable salt thereof. Phospholipids may be selected or engineered to provide improved performance in inducing desired immune responses, such as increasing the production of antibodies associated with target antigens, to the lipid nanoparticles or vaccines comprising them. In some embodiments, the lipid nanoparticles comprise one type of phospholipid. In other embodiments, the lipid nanoparticles comprise two or more types of phospholipids, for example, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, or ten or more types of phospholipids.

[0088] In some instances, the provided lipid nanoparticles and vaccines comprising lipid nanoparticles have exhibited the ability to induce strong immune responses, in part because the phospholipids in the lipid nanoparticles have a net neutral charge at physiological pH. Lipid nanoparticles comprising such neutral phospholipids have been shown herein to advantageously stimulate high antibody production. Phospholipids may include, for example, phosphatidylcholine, phosphatidylethanolamine, or combinations thereof, or constitute thereof.

[0089] Phosphatidylcholine lipids suitable for use with the provided lipid nanoparticles include, for example, 1,2-distearyl-sn-glycerol-3-phosphate choline (DSPC), 1,2-decanoyl-sn-glycerol-3-phosphate choline, 1,2-diundecanoyl-sn-glycerol-3-phosphate choline, 1,3-dipalmitoyl-rac-glycerol-2-phosphate choline, 1,2-dilauroyl-sn-glycerol-3-phosphate choline (DLPC), 1 2-Ditridecanoyl-sn-glycerol-3-phosphate choline, 1,2-dimyristoyl-sn-glycerol-3-phosphate choline (DMPC), 1,2-dipentadecanoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1,2-diheptadecanoyl-sn-glycerol-3-phosphate choline, 1,2-dinonadecanoyl-sn-glycerol-3-phosphate choline, 1,2-di-di- Arachidoyl-sn-glycerol-3-phosphate choline, 1,2-bisoctadecenoyl-sn-glycerol-3-phosphate choline, 1,2-bis[(8Z)octadecenoyl]-sn-glycerol-3-phosphate choline, 1,2-dimyristenoyl-sn-glycerol-3-phosphate choline, 1,2-ditransmyristenoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline, 1,2-ditranspalmitoyl- sn-glycerol-3-phosphate choline, 1,2-dicarboxyloyl-sn-glycerol-3-phosphate choline, 1,2-dioleoyl-sn-glycerol-3-phosphate choline (DOPC), 1,2-ditransoleoyl-sn-glycerol-3-phosphate choline, 1,2-dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-dilinolenoyl-sn-glycerol-3-phosphate choline, 1,2-bis(eicosenoyl-sn-glycerol-3-phosphate choline), 1,2-Diarachidonic-sn-glycerol-3-phosphate choline, 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate choline, 1-myristoyl-2-palmitoyl-sn-glycerol-3-phosphate choline (MPPC), 1-myristoyl-2-stearoyl-sn-glycerol-3-phosphate choline (MSPC), 1-palmitoyl-2-myristoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-stearoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-oleoyl-glycerol-3-phosphate choline (POPC), 1-palmitoyl-2-linoleoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-arachidonic-sn-glycerol-3-phosphate choline (PAPC) 1-Stearyl-2-myristoyl-sn-glycerol-3-phosphate choline (SMPC), 1-stearoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-oleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-arachidonicoyl-sn-glycerol-3-phosphate choline, 1-oleoyl-2-myristoyl-sn-glycerol-3-phosphate choline (OMPC), 1-oleoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-oleoyl-2-stearoyl-sn-glycerol-3-phosphate choline, 1-(8Z-octadecenoyl)-2-palmitoyl-sn-glycerol-3-phosphate choline, or combinations thereof.

[0090] Phosphatidylethanolamine lipids suitable for use with the provided lipid nanoparticles include, for example, 1,2-bis(heptadecanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-decanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilauroyl-sn-glycerol-3-phosphate ethanolamine (DLPE), 1,2-bis(pentadecanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine (DPPE), 1,2-di... Stearoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dimyristoyl-sn-glycerol-3-phosphate ethanolamine (DMPE), 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), 1,2-ditransoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine 1,2-Didocoshexaenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-disarachidonicyl-sn-glycerol-3-phosphate ethanolamine (DAPE), 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-linoleoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine (POPE), 1-stearoyl-2-oleoyl- sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-arachidonico-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-arachidonico-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine or combinations thereof.

[0091] In addition to the type of phospholipid, the amount of phospholipid included in the provided lipid nanoparticles has also been shown to provide the particles with their advantageous properties. The phospholipids present in the provided lipid nanoparticles may account for, for example, from about 3 mol% to about 20 mol% of the total lipids present in the particles, for example, from about 5 mol% to about 20 mol%, from about 8 mol% to about 20 mol%, from about 10 mol% to about 20 mol%, from about 3 mol% to about 15 mol%, from about 5 mol% to about 15 mol%, from about 8 mol% to about 15 mol%, from about 10 mol% to about 15 mol%, or from about 8 mol% to about 12 mol%. In some embodiments, the phospholipids present in the lipid nanoparticles account for about 5 mol%, from about 6 mol%, from about 7 mol%, from about 8 mol%, from about 9 mol%, from about 10 mol%, from about 11 mol%, from about 12 mol%, from about 13 mol%, from about 14 mol%, or from about 15 mol% of the total lipids present in the particles.

[0092] 5. Nucleic acid

[0093] The lipid nanoparticles disclosed herein typically include nucleic acids. The composition of the lipid nanoparticles can be selected or configured such that the nucleic acids present in the lipid nanoparticles are resistant to degradation by nucleases in aqueous solutions. In some embodiments, at least 50% of the nucleic acid is encapsulated within the lipid nanoparticles; in one embodiment, at least 75% of the nucleic acid is encapsulated within the lipid nanoparticles; in one embodiment, at least 90% of the nucleic acid is encapsulated within the lipid nanoparticles; and in one embodiment, the nucleic acid is completely encapsulated within the lipid nanoparticles.

[0094] In some embodiments, this disclosure provides lipid nanoparticle formulations comprising a plurality of lipid nanoparticles or groups of lipid nanoparticles. In some embodiments, nucleic acids are completely encapsulated within the lipid portions of the lipid nanoparticles, such that the plurality of lipid nanoparticles or groups of lipid nanoparticles comprises approximately 30% to approximately 100%, approximately 40% to approximately 100%, approximately 50% to approximately 100%, approximately 60% to approximately 100%, approximately 70% to approximately 100%, approximately 80% to approximately 100%, approximately 90% to approximately 100%, approximately 30% to approximately 95%, approximately 40% to approximately 95%, approximately 50% to approximately 95%, approximately 60% to approximately 95%, approximately 70% to approximately 95%, approximately 80% to approximately 95%, and approximately 85% to approximately 100%. Nucleic acid is encapsulated in lipid nanoparticles of 95%, about 90% to about 95%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, or at least about 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% (or any part thereof or range thereof).

[0095] Nucleic acids present in the lipid nanoparticles described herein may include or be composed of any known form of nucleic acid. Nucleic acids as used herein may be single-stranded DNA or RNA (e.g., ssDNA or ssRNA), or double-stranded DNA or RNA (e.g., dsDNA or dsRNA), or DNA-RNA hybrids. Single-stranded nucleic acids include, for example, mRNA, self-amplifying RNA (saRNA), and circular RNA (circRNA).

[0096] Nucleic acids can have various lengths, typically depending on their specific form. For example, in certain embodiments, the length of mRNA, plasmid, or gene can be from about 500 to about 100,000 nucleotides. In certain embodiments, the length of oligonucleotides can range from about 10 to about 100 nucleotides. In various related embodiments, oligonucleotides, which can be single-stranded, double-stranded, or triple-stranded, can range in length from about 10 to about 60 nucleotides, from about 15 to about 60 nucleotides, from about 20 to about 50 nucleotides, from about 15 to about 30 nucleotides, or from about 20 to about 30 nucleotides.

[0097] In some embodiments, the nucleic acids in the provided lipid nanoparticles comprise or consist of modified or substituted polynucleotides or oligonucleotides. In some cases, modified or substituted polynucleotides and oligonucleotides may be preferred over natural forms due to their properties such as enhanced cellular uptake, reduced immunogenicity, and increased stability in the presence of nucleases.

[0098] a) Proteins of interest

[0099] The nucleic acids in the provided lipid nanoparticles typically encode a protein of interest or a fragment thereof. The protein of interest can be, for example, any protein that can be expressed by a target cell or target organism, i.e., the cell or organism to which the lipid nanoparticles are applied. In some embodiments, the protein of interest is a protein that can be secreted by a target cell (e.g., a target cell of a target organism). In some embodiments, the protein of interest is a protein that can be displayed on the surface of a target cell.

[0100] In a preferred embodiment, the protein of interest is an antigen. The presence of antigen in the lipid nanoparticles and the provided vaccine comprising lipid nanoparticles allows the lipid nanoparticles to induce an immune response in the subject to whom the lipid nanoparticles or vaccine are administered. For example, after administration of the provided lipid nanoparticles or vaccine to a subject, and as a result of this administration, the subject may produce antibodies associated with an antigen encoded by a nucleic acid in the lipid nanoparticles.

[0101] The nucleic acids in the provided lipid nanoparticles can encode infection-associated antigens. In some instances, the antigens encoded by the nucleic acids in the provided lipid nanoparticles are derived from pathogens. These pathogens can be bacterial pathogens. For example, pathogens can be *Achromobacter xylosoxidans*, *Acinetobacter baumannii*, *Actinomyces* such as *Actinomycesisraelii*, *Aeromonas*, *Bacillus*, *Bacteroides fragilis*, *Bacteroides melaninogenicus*, *Bartonella*, *Bordetella pertussis*, *Borrelia*, *Brucella*, *Burkholderia*, *Campylobacter*, *Capnocytophaga*, *Chlamydia pneumoniae*, and *Chlamydia psittaci*. The following bacteria are listed: *Psittaci*, *Citrobacter*, *Clostridium*, *Corynebacterium*, *Coxiella burnetii*, *Ehrlichia*, *Eikenella corrodens*, *Enterobacter*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Francisella tularensis*, *Fusobacterium necrophorum*, *Gardnerella vaginalis*, *Haemophilus*, and *Helicobacter pylori*. pylori, Klebsiella, Lactobacillus, Legionella, Leptospira, Listeria monocytogenes, MoraxellaThe following bacteria are listed: *Catarrhalis*, *Morganella*, *Mycoplasma pneumoniae*, *Neisseria*, *Nocardia*, *Pasteurella multocida*, *Peptostreptococcus*, *Porphyromonas gingivalis*, *Propionibacterium acnes*, *Proteus*, *Providencia*, *Pseudomonas aeruginosa*, *Salmonella*, *Serratia marcescens*, *Shigella*, *Staphylococcus epidermidis*, *Staphylococcus hominis*, and *Staphylococcus hemolyticus*. Staphylococcus haemolyticus, Staphylococcus aureus, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus anginosus group, Streptococcus pneumoniae, Streptococcus pyogenes (groups A, B, C, G and / or F), Treponema pallidum, Vibrio, or combinations thereof.

[0102] In some instances, the antigens encoded by the nucleic acids in the provided lipid nanoparticles are derived from fungal pathogens. For example, pathogens can include *Cryptococcus neoformans*, *Candida auris*, *Aspergillus fumigatus*, *Candida albicans*, *Nakaseomyces glabrata* (Candida glabrata), *Histoplasma*, fungal mycomas, *Mucorales*, *Fusarium*, *Candida tropicalis*, *Candida parapsilosis*, *Scedosporium*, *Cryptococcus gattii*, *Lomentosporaprolificans*, *Talaromyces marneffei*, *Coccidioides*, and *Pneumocystis*. jirovecii), Pichiakudriavzeveii (Candida krusei), Paracoccidioides, or combinations thereof.

[0103] In some instances, the antigens encoded by the nucleic acids in the provided lipid nanoparticles are derived from protozoan pathogens. For example, the pathogens could be *Cryptosporidium*; *Toxoplasma gondii*; *Plasmodium* species such as *Plasmodium malariae*, *Plasmodium falciparum*, *Plasmodium vivax*, and *Plasmodium ovale*; *Trypanosoma cruzi* and *Trypanosoma brucei*; *Leishmania*; *Giardia duodenalis*; *Entamoeba histolytica*; *Naegleria fowleri*; *Babesia microti*; and *Balamuthia*. The genera *Mandrillaris*, *Blastocystishominis*, *Trichomonas vaginalis*, *Schistosoma*, or combinations thereof.

[0104] In some instances, the antigens encoded by the nucleic acids in the provided lipid nanoparticles are derived from worm pathogens. For example, pathogens can include Ascaris lumbricoides, Trichuris trichiura, Necator americanus, Strongyloides stercoralis, Ancylostoma duodenale, Hymenolepis nana, Taeniasaginata, Enterobius, Fasciola hepatica, Schistosoma mansoni, Toxocara canis, Toxocara cati, Wuchereria bancrofti, Brugia malayi, Onchocercavolvulus, Trichostrongylus, and Dracunculus. The following are listed: *Medinensis*, *Baylisascaris*, *Echinococcus*, *Taenia multiceps*, *Taenia serialis*, *Taenia glomerata*, *Taenia brauna*, *Clonorchis sinensis*, *Fasciolopsis buski*, *Opisthorchis*, *Paragonimus*, *Schistosoma*, *Moniliformis*, or combinations thereof.

[0105] In some instances, the antigens encoded by the nucleic acids in the provided lipid nanoparticles are derived from viral pathogens. For example, the antigens may be derived from coronaviruses (e.g., SARS-CoV-1, SARS-CoV-2, MERS-CoV), influenza viruses (e.g., influenza A, B, and C viruses), filoviruses (e.g., Ebola virus, Marburg virus), arenaviruses (e.g., Lassa virus, Junin virus, Machupo virus, Guanarito virus, Sabiavirus), Zika virus, rabies virus, rhinovirus, simian immunodeficiency virus (SIV), human immunodeficiency virus (HIV), hepatitis viruses (e.g., hepatitis C virus), herpes simplex virus, human papillomavirus (HPV), or Epstein-Barr virus. In a specific embodiment, the infectious disease antigen is a SARS-CoV-2 protein selected from the group consisting of: S (spike) protein, E (enveloped) protein, M (membrane) protein, N (nucleocapsid) protein, and antigenic fragments thereof. In other embodiments, the infectious disease antigen is a hemagglutinin (HA) protein from a Paramyxoviridae or Orthomyxoviridae virus (e.g., influenza virus). Examples 2, 4, and 5 demonstrate the use of the provided lipid nanoparticles to encapsulate the nucleic acid encoding hemagglutinin, i.e., mRNA.

[0106] In some instances, the antigen encoded by the nucleic acid in the provided lipid nanoparticles is derived from a pathogenic toxin. The antigen may be associated with any non-enzymatic product of any pathogen (e.g., any of the bacterial, fungal, protozoan, worm, or viral pathogens described above), wherein the pathogen product is harmful to the subject infected with the pathogen. In some instances, the antigen is derived from a pathogenic adhesion element, i.e., any product of any pathogen (e.g., any of the bacterial, fungal, protozoan, worm, or viral pathogens described above), wherein the pathogen product participates in the adhesion of the pathogen to the cells of the subject infected with the pathogen.

[0107] b) mRNA

[0108] The nucleic acid encoding the protein of interest in the provided lipid nanoparticles may include or be composed of an RNA molecule encoding or a fragment thereof. In some instances, the nucleic acid in the provided lipid nanoparticles includes or is composed of one or more messenger RNA (mRNA) molecules (e.g., a cocktail of mRNA molecules). The mRNA molecules may be selected or engineered for transfer to cells in a subject (e.g., a mammal, such as a human) to which the provided lipid nanoparticles or vaccine are administered. The mRNA molecules may encode one or more antigens expressed intracellularly to elicit immunity against a disease. Thus, the compositions and methods described herein can be used, for example, to prevent infectious diseases caused by pathogens such as viruses (e.g., coronaviruses, such as SARS-CoV-2) by expressing antigenic peptides (e.g., mRNA molecules encoding viral proteins such as S (spike), E (enveloping), M (membrane), or N (nucleocapsid) proteins or antigenic fragments thereof) in an organism (e.g., a mammal, such as a human) to generate an immune response targeting the pathogen by stimulating the adaptive immune system to produce antibodies.

[0109] In some embodiments, the mRNA molecules are completely encapsulated within lipid particles. In some instances, the RNA in the provided lipid nanoparticles or the provided population of nanoparticles comprises a mixture of one or more types of mRNA with one or more other types of RNA (e.g., gRNA, siRNA, miRNA, etc.). Regarding formulations containing mRNA mixtures, different types of mRNA species present in the mixture (e.g., mRNAs with different sequences) may be co-encapsulated in the same particle, or each type of mRNA species present in the mixture may be encapsulated in a separate particle. The mRNA mixture may be formulated in the particles described herein using a mixture of two or more separate mRNAs (each having a unique sequence) at the same, similar, or different concentrations or molar ratios. In one embodiment, a mixture of mRNAs (corresponding to multiple mRNAs with different sequences) is formulated using each mRNA species at the same, similar, or different concentrations or molar ratios, and different types of mRNAs are co-encapsulated in the same particle. In another embodiment, each type of mRNA present in the mixture is encapsulated in different particles at the same, similar, or different mRNA concentrations or molar ratios, and the resulting particles (each containing a different mRNA payload) are administered individually (e.g., at different times depending on a prophylactic or therapeutic regimen) or in combination as a single unit dose (e.g., with a pharmaceutically acceptable carrier). In a particular embodiment, the lipid particles are serum stable, resistant to nuclease degradation, and substantially nontoxic to mammals (such as humans).

[0110] (1) Modification of mRNA

[0111] The mRNA molecules present in the provided lipid nanoparticles may include one, two, or more nucleoside modifications. In some embodiments, the modified mRNA exhibits reduced degradation in the cells into which it is introduced, relative to the corresponding unmodified mRNA.

[0112] In some embodiments, the modified nucleoside comprises or is composed of the following: pyridine-4-ketoribonucleotide, 5-aza-uridine, 2-thio-5-aza-uridine, 2-thiouridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuridine, 3-methyluridine, 5-carboxymethyluridine, 1-carboxymethyl-pseudouridine, 5-propynyluridine, 1-propynyl-pseudouridine, 5-taurylmethyluridine, 1-taurylmethyl-pseudouridine, 5-taurylmethyl-2-thio-uridine, 1-tauryl... Sulfonylmethyl-4-thio-uridine, 5-methyl-uridine, 1-methyl-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-denitro-pseudouridine, 2-thio-1-methyl-1-denitro-pseudouridine, dihydrouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, or any combination thereof.

[0113] In some embodiments, the modified nucleosides include or consist of the following: 5-aza-cytidine, pseudocytidine, 3-methylcytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-hydroxymethylcytidine, 1-methyl-pseudocytidine, pyrrolocytidine, pyrrolopseudocytidine, 2-thiocytidine, 2-thio-5-methylcytidine, 4-thio-pseudocytidine, 4-thio-1-methyl-pseudocytidine, 4- Thio-1-methyl-1-denitro-pseudo-isocytidine, 1-methyl-1-denitro-pseudo-isocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudo-isocytidine, 4-methoxy-1-methyl-pseudo-isocytidine, or any combination thereof.

[0114] In other embodiments, the modified nucleosides include or consist of the following: 2-aminopurine, 2,6-diaminopurine, 7-deazo-adenine, 7-deazo-8-aza-adenine, 7-deazo-2-aminopurine, 7-deazo-8-aza-2-aminopurine, 7-deazo-2,6-diaminopurine, 7-deazo-8-aza-2,6-diaminopurine, 1-methyladenosine, N6-methyladenosine. Glycosides, N6-isopentenyl adenosine, N6-(cis-hydroxyisopentenyl) adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine, N6-glycylcarbamoyl adenosine, N6-threonylcarbamoyl adenosine, 2-methylthio-N6-threonylcarbamoyl adenosine, N6,N6-dimethyl adenosine, 7-methyl adenosine, 2-methylthio-adenosine, and 2-methoxy-adenosine.

[0115] In some embodiments, the modified nucleosides comprise or consist of the following: 5'-O-(1-thiophosphate)-adenosine, 5'-O-(1-thiophosphate)-cytidine, 5'-O-(1-thiophosphate)-guanosine, 5'-O-(1-thiophosphate)-uridine, 5'-O-(1-thiophosphate)-pseuuridine, or combinations thereof. An α-thiosubstituted phosphate moiety is provided to impart stability to the RNA polymer via a non-natural thiophosphate backbone bond. The thiophosphate RNA polymer exhibits increased nuclease resistance and thus a longer half-life in the cellular environment. The thiophosphate-linked nucleic acids are also expected to reduce the innate immune response through weaker binding / activation of cellular innate immune molecules.

[0116] In some embodiments, for example, if precise timing of protein production is required, it is necessary to degrade the modified nucleic acid introduced into the cell within the cell. Therefore, this disclosure provides modified nucleic acids containing degradation domains that can be directed within the cell.

[0117] In other embodiments, the modified nucleosides include or consist of the following: inosine, 1-methyl-inosine, wyoside, wyoside, 7-deazo-guanosine, 7-deazo-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deazo-guanosine, 6-thio-7-deazo-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, N2-methylguanosine, N2,N2-dimethylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2-dimethyl-6-thio-guanosine, or combinations thereof.

[0118] (2) Optional mRNA components

[0119] In another embodiment, the mRNA molecule present in the provided lipid nanoparticles may include other optional components. These optional components include, but are not limited to, untranslated regions, Kozak sequences, intronic nucleotide sequences, internal ribosome entry sites (IRES), 5' caps, and poly-A tails. For example, a 5' untranslated region (UTR) and / or a 3' UTR may be included, wherein either or both may independently contain one or more different nucleoside modifications. In such embodiments, nucleoside modifications may also be present in translatable regions. mRNA molecules containing Kozak sequences are also provided. Additionally, mRNA molecules containing one or more intronic nucleotide sequences that can be excised from the mRNA sequence are provided herein.

[0120] (a) Untranslated Region (UTR)

[0121] The untranslated region (UTR) of a gene is transcribed but not translated. The 5' UTR begins at the transcription start site and continues to the start codon, but does not include the start codon; while the 3' UTR begins immediately after the stop codon and continues until the transcription termination signal. Increasing evidence suggests that the UTR plays a regulatory role in the stability and translation of mRNA molecules. Regulatory features of the UTR can be incorporated into the mRNA used in the lipid particles described in this paper to increase molecular stability. Specific features can also be incorporated to ensure controlled downregulation of the transcript, preventing it from being misdirected to unwanted tissue or organ sites.

[0122] (b) 5' with a hat

[0123] The 5' cap structure of mRNA participates in nuclear export, thereby increasing mRNA stability. It also binds to mRNA cap-binding protein (CBP), which, through association with poly(A)-binding proteins, forms mature circular mRNA species responsible for mRNA stability and translation capacity within the cell. The cap further facilitates the removal of 5' proximal introns during mRNA splicing.

[0124] mRNA molecules can be 5'-capped, thereby creating a 5'-ppp-5'-triphosphate bond between the terminal guanylic acid cap residue and the 5'-terminal sense nucleotide. This 5'-guanylic acid cap can then be methylated to produce an N7-methyl-guanylic acid residue. The ribose of the terminal and / or anti-terminal transcribed nucleotide of the 5' end of the mRNA can also optionally be 2'-O-methylated. 5'-decapping via hydrolysis and cleavage of the guanylic acid cap structure can target the mRNA molecule for degradation.

[0125] (c) IRES sequence

[0126] mRNAs containing an internal ribosome entry site (IRES) can also be used in the lipid nanoparticles described herein. The IRES can act as a single ribosome binding site or as one of multiple ribosome binding sites for the mRNA. mRNAs containing more than one functional ribosome binding site can encode several peptides or polypeptides that are independently translated by the ribosome (“polycistronic mRNA”). When the mRNA has an IRES, a second translatable region is optionally provided further. Examples of IRES sequences include, but are not limited to, those from picornaviruses (e.g., FMDV), pest viruses (e.g., CFFV), poliovirus (PV), encephalomyocarditis virus (ECMV), foot-and-mouth disease virus (FMDV), hepatitis C virus (HCV), classical swine fever virus (CSFV), murine leukemia virus (MLV), simian immunodeficiency virus (S1V), and cricket paralysis virus (CrPV).

[0127] (d) Poly-A tail

[0128] During RNA processing, a long chain of adenine nucleotides (poly-A tail) can be added to polynucleotide molecules such as mRNA to increase stability. Post-transcriptional, the 3' end of the transcript can be immediately cleaved to release the 3' hydroxyl group. Then, poly-A polymerase adds the adenine nucleotide chain to the RNA. This process, known as polyadenylation, adds a poly-A tail of between 100 and 250 residues in length.

[0129] Typically, the poly-A tail is longer than 30 nucleotides. In some embodiments, the poly-A tail is longer than 35 nucleotides (e.g., at least or greater than about 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2,000, 2,500, and 3,000 nucleotides). In some embodiments, the length of the poly-A tail can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% longer than the mRNA. In other embodiments, the poly-A tail can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the total length of the mRNA.

[0130] (3) mRNA molecule production

[0131] Methods for isolating RNA, synthesizing RNA, hybridizing nucleic acids, preparing and screening cDNA libraries, and performing PCR are well known in the art (see, for example, Gubler and Hoffman, *Gene*, 25:263-269 (1983); Sambrook et al., *Molecular Cloning, A Laboratory Manual* (2nd edition, 1989)). PCR methods are also well known in the art (see, for example, U.S. Patents 4,683,195 and 4,683,202; *PCR Protocols: A Guide to Methods and Applications* (edited by Innis et al., 1990)). Expression libraries are also well known to those skilled in the art. Further foundational texts disclosing the general methods of use in this disclosure include Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel et al., eds., 1994). In some embodiments, mRNA molecules are produced by in vitro transcription and then purified. Standard techniques for purifying mRNA (e.g., mRNA produced by in vitro transcription) are well known in the art and include, for example, oligomeric (dT) affinity purification, cellulose-based purification, and other chromatographic methods. Examples of available mRNA purification techniques are provided by Zhang, J. et al., *Pharmaceutics*, 15:2182 (2023).

[0132] In some embodiments, the provided lipid nanoparticles contain mRNA synthesized from a DNA template. Methods for synthesizing mRNA from a DNA template are well known and generally involve the use of an enzyme (e.g., T7 RNA polymerase and / or its derivatives, such as optimized alternative enzymes), nucleotides (optionally including modified nucleotides as described herein), and optional mRNA components (e.g., a 5' cap). In some embodiments, the lipid nanoparticles contain mRNA generated by in vitro transcription using a commercially available kit. Commercially available kits suitable for generating mRNA contained in the provided lipid nanoparticles include, for example, the MEGASCRIPT™ T7 Transcription Kit available from Thermo Fisher Scientific. Alternatively or additionally, the mRNA used with the provided lipid nanoparticles can be generated using chemical synthesis methods, such as those described by Abe et al., ACS Chem. Biol. 2022, 17, 6, 1308-1314. In another embodiment, the lipid nanoparticles comprise mRNA produced using an mRNA printer (e.g., any of those mRNA printers reviewed in Sheridan, Nature Biotechnol, 2022, 40, 1160-1162).

[0133] In some embodiments, the mRNA generated by any one or more of the methods described herein is purified prior to its use in forming one or more of the provided lipid nanoparticles. Suitable mRNA purification techniques for use with the mRNA in the provided lipid nanoparticles include, but are not limited to, HPLC purification, cellulose purification, tangential flow filtration, bead-based purification (e.g., purification with Dynabead), silica-based purification, precipitation, and combinations thereof. Non-limiting examples of mRNA purification are described, for example, in International Patent Application Publication No. WO 2018 / 006052 A1.

[0134] c) circRNA

[0135] In some instances, the nucleic acids in the provided lipid nanoparticles comprise one or more circular RNA (circRNA) molecules, such as mixtures of circRNA molecules, or are composed of them. The circRNA molecules can be selected or engineered for transfer to cells within the body of a subject (e.g., a mammal, such as a human) to which the provided lipid nanoparticles or vaccine are administered. The circRNA molecules may encode one or more antigens expressed intracellularly to elicit immunity against a disease. Therefore, the compositions and methods described herein can be used, for example, to prevent infectious diseases caused by pathogens such as viruses (e.g., coronaviruses, such as SARS-CoV-2) by expressing antigenic peptides (e.g., circRNA molecules encoding viral proteins such as S (spike), E (enveloping), M (membrane), or N (nucleocapsid) proteins or antigenic fragments thereof) to stimulate the adaptive immune system to produce antibodies targeting the pathogen in an organism (e.g., a mammal, such as a human).

[0136] In some embodiments, the circRNA molecules are completely encapsulated within lipid particles. In some instances, the RNA in the provided lipid nanoparticles or the provided population of nanoparticles comprises a mixture of one or more types of circRNAs with one or more other types of RNA (e.g., gRNA, siRNA, miRNA, etc.). Regarding formulations containing circRNA mixtures, different types of circRNAs present in the mixture (e.g., circRNAs with different sequences) can be co-encapsulated in the same particle, or each type of circRNA present in the mixture can be encapsulated in a separate particle. CircRNA mixtures can be formulated in particles described herein using mixtures of two or more separate circRNAs (each having a unique sequence) at the same, similar, or different concentrations or molar ratios. In one embodiment, a mixture of circRNAs (corresponding to multiple circRNAs with different sequences) is formulated using each type of circRNA at the same, similar, or different concentrations or molar ratios, and different types of circRNAs are co-encapsulated in the same particle. In another embodiment, each type of circRNA present in the mixture is encapsulated in different particles at the same, similar, or different circRNA concentrations or molar ratios, and the resulting particles (each containing a different circRNA payload) are administered individually (e.g., at different times depending on a prophylactic or therapeutic regimen) or in combination as a single unit dose (e.g., with a pharmaceutically acceptable carrier). In a particular embodiment, the lipid particles are serum stable, resistant to nuclease degradation, and substantially nontoxic to mammals (e.g., humans).

[0137] In another embodiment, the circRNA molecule present in the provided lipid nanoparticles may include other optional components. These optional components include, but are not limited to, untranslated regions, Kozak sequences, intronic nucleotide sequences, internal ribosome entry sites (IRES), in-frame 2A peptide coding sequences, and m6A modified motif sequences. For example, a 5' untranslated region (UTR) and / or a 3' UTR may be included, wherein either or both may independently contain one or more different nucleoside modifications, such as any of the nucleoside modifications described in sections C.5.b and C.5.b(1). In such embodiments, nucleoside modifications may also be present in the translatable region. CircRNA molecules containing Kozak sequences are also provided. Additionally, circRNA molecules containing one or more intronic nucleotide sequences that can be excised from the circRNA sequence are provided herein.

[0138] Various methods available in the art can be used to generate circRNA. For example, U.S. Patent No. 6,210,931 teaches a method for synthesizing circRNA by inserting a DNA fragment into a plasmid containing a sequence capable of spontaneous cutting and self-circularization. U.S. Patent No. 5,773,244 teaches the generation of circRNA by preparing a DNA construct encoding an RNA cyclase ribozyme, expressing the DNA construct as RNA, and then subjecting the RNA to self-splicing, which produces intron-free circRNA in vitro. International Patent Application Publication WO 1992 / 001813 teaches a method for preparing single-stranded circular nucleic acids by synthesizing a linear polynucleotide, combining the linear polynucleotide with a complementary linking oligonucleotide under hybridization conditions, and linking the linear polynucleotide. Other methods for generating circRNA are provided, for example, in International Patent Application Publications WO 2015 / 034925 and WO 2016 / 011222.

[0139] d) saRNA

[0140] In some instances, the nucleic acids in the provided lipid nanoparticles comprise one or more self-amplifying RNA (saRNA) molecules, such as mixtures of saRNA molecules, or are composed of them. The saRNA molecules can be selected or engineered for transfer to cells within the body of a subject (e.g., a mammal, such as a human) to which the provided lipid nanoparticles or vaccine are administered. The saRNA molecules may encode one or more antigens expressed intracellularly to elicit immunity against a disease. Therefore, the compositions and methods described herein can be used, for example, to prevent infectious diseases caused by pathogens such as viruses (e.g., coronaviruses, such as SARS-CoV-2) by expressing antigenic peptides (e.g., saRNA molecules encoding viral proteins such as S (spike), E (enveloping), M (membrane), or N (nucleocapsid) proteins or antigenic fragments thereof) to stimulate the adaptive immune system to produce antibodies targeting pathogens in an organism (e.g., a mammal, such as a human).

[0141] In some embodiments, the saRNA molecules are completely encapsulated within lipid particles. In some instances, the RNA in the provided lipid nanoparticles or the provided population of nanoparticles comprises a mixture of one or more types of saRNA with one or more other types of RNA (e.g., gRNA, siRNA, miRNA, etc.). Regarding formulations containing a mixture of saRNAs, different types of saRNAs present in the mixture (e.g., saRNAs with different sequences) may be co-encapsulated in the same particle, or each type of saRNA present in the mixture may be encapsulated in a separate particle. The saRNA mixture may be formulated in the particles described herein using a mixture of two or more separate saRNAs (each having a unique sequence) at the same, similar, or different concentrations or molar ratios. In one embodiment, a mixture of saRNAs (corresponding to multiple saRNAs with different sequences) is formulated using each saRNA type at the same, similar, or different concentrations or molar ratios, and different types of saRNAs are co-encapsulated in the same particle. In another embodiment, each type of saRNA present in the mixture is encapsulated in different particles at the same, similar, or different saRNA concentrations or molar ratios, and the resulting particles (each containing a different saRNA payload) are administered individually (e.g., at different times depending on a prophylactic or therapeutic regimen) or in combination as a single unit dose (e.g., with a pharmaceutically acceptable carrier). In a particular embodiment, the lipid particles are serum stable, resistant to nuclease degradation, and substantially nontoxic to mammals (e.g., humans).

[0142] In another embodiment, the saRNA molecule present in the provided lipid nanoparticles may include other optional components. These optional components include, but are not limited to, untranslated regions, Kozak sequences, intronic nucleotide sequences, internal ribosome entry sites (IRES), caps, and poly-A tails. For example, a 5' untranslated region (UTR) and / or a 3' UTR may be included, wherein either or both may independently contain one or more different nucleoside modifications, such as any of the nucleoside modifications described in sections C.5.b and C.5.b(1). In such embodiments, nucleoside modifications may also be present in translatable regions. saRNA molecules containing Kozak sequences are also provided. Additionally, saRNA molecules containing one or more intronic nucleotide sequences that can be excised from the saRNA sequence are provided herein.

[0143] D. Pharmaceutical compositions and formulations

[0144] On the other hand, this disclosure provides a pharmaceutical composition comprising one or more of the lipid nanoparticles or vaccines described in Section C herein. In some embodiments, the pharmaceutical composition further comprises a therapeutically effective amount of a pharmaceutically acceptable excipient. Additionally or alternatively, the pharmaceutical composition may comprise a pharmaceutically acceptable carrier.

[0145] Pharmaceutically acceptable carriers (e.g., physiological saline or phosphate-buffered saline) can be selected based on the route of administration and standard pharmaceutical practice. Physiologically buffered saline (e.g., 135–150 mM NaCl) is typically used as a pharmaceutically acceptable carrier. Other suitable carriers include, for example, water, buffered water, 0.4% saline, 0.3% glycine, and glycoproteins such as albumin, lipoproteins, and globulins, which enhance stability. Further suitable carriers are described, for example, in *Remington: The Science and Practice of Pharmacy*, 23rd edition (2020). Pharmaceutically acceptable carriers are typically added after particle formation. Therefore, after particle formation, the particles can be diluted with a pharmaceutically acceptable carrier (such as physiologically buffered saline).

[0146] Examples of suitable excipients for use with the provided pharmaceutical composition include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline, syrup, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, and polyacrylic acid (such as carbopol, e.g., carbopol 941, carbopol 980, carbopol 981, etc.).

[0147] The provided pharmaceutical compositions may additionally include: lubricants such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifiers; suspending agents; preservatives such as methylparaben, ethylparaben, and propylparaben (i.e., para-hydroxybenzoate); pH adjusters such as inorganic and organic acids and bases; sweeteners; colorants; and / or flavoring agents. The compositions may also contain biodegradable polymer beads, dextran, and cyclodextrin inclusion complexes.

[0148] Pharmaceutical compositions that are liquid compositions, whether or not they are solutions, suspensions, or other similar forms, may include one or more of the following: sterile diluents, such as water for injection, saline solutions (preferably physiological saline), Ringer's solution, or isotonic sodium chloride; fixed oils, such as synthetic mono- or diglycerides of glycerol, polyethylene glycol, glycerol, cyclodextrin, propylene glycol, or other solvents that can act as solvents or suspension media; antimicrobial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as amino acids, acetates, citrates, or phosphates; detergents, such as nonionic surfactants or polyols; and agents for adjusting the tension, such as sodium chloride or dextrose. Liquid compositions may include aqueous or oily suspensions or emulsions containing sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or sterile aqueous solutions and similar pharmaceutical mediators. Aqueous solutions in saline are also commonly used for injection. Ethanol, glycerol, propylene glycol, and liquid polyethylene glycol (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils can also be used. The desired particle size can be maintained in the case of a dispersion system by using coatings such as lecithin, and appropriate flowability can be maintained by using surfactants.

[0149] The provided pharmaceutical composition for administration is preferably sterile. Microbial action can be prevented by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and thimerosal. The composition for administration can be encapsulated in ampoules, disposable syringes, or multi-dose vials made of glass, plastic, or other materials.

[0150] For oral administration, the provided pharmaceutical compositions may be in the form of tablets, lozenges, capsules, emulsions, suspensions, solutions, syrups, sprays, powders, and / or sustained-release formulations. Suitable excipients for oral administration include pharmaceutical-grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, gelatin, sucrose, magnesium carbonate, etc.

[0151] For topical application, the provided pharmaceutical composition may be in the form of emulsion, lotion, gel, cream, jelly, solution, suspension, ointment, and / or transdermal patch. For inhalation delivery, the composition may be delivered as a dry powder or in liquid form via a nebulizer. For parenteral application, the composition may be in the form of a sterile injectable solution and / or sterile packaged powder. Preferably, the injectable solution is prepared at a pH of about 4.5 to about 7.5.

[0152] The concentration of lipid nanoparticles in the provided drug formulation can vary widely, for example, from less than about 0.05% by weight, typically or at least about 2% to about 5%, up to about 10% to about 90%, and can be selected primarily by fluid volume, viscosity, etc., depending on the specific administration modality chosen. For example, the concentration can be increased to reduce the treatment-related fluid load. This may be particularly desirable in patients with atherosclerosis-related congestive heart failure or severe hypertension. Alternatively, lipid nanoparticles composed of irritating lipids can be diluted to low concentrations to reduce inflammation at the application site.

[0153] The provided pharmaceutical compositions can be sterilized using conventional, well-known sterilization techniques. Aqueous solutions can be packaged for use or filtered and lyophilized under aseptic conditions; the lyophilized formulation is combined with the sterile aqueous solution prior to administration. The compositions may contain pharmaceutically acceptable excipients close to those required for physiological conditions, such as pH adjusters and buffers, tonicants, etc., for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, and / or calcium chloride. Additionally, lipid nanoparticle suspensions may include lipid protectants that protect lipids from free radical and lipid peroxidation damage during storage. Lipophilic free radical quenchers, such as α-tocopherol, and water-soluble iron-specific chelating agents (such as ferrioxamine) are suitable.

[0154] E. Reagent kit

[0155] On the other hand, this disclosure provides kits to facilitate and / or standardize the use of the materials described herein (i.e., lipid nanoparticles and vaccines described in Section C and / or pharmaceutical compositions described in Section D), and to facilitate the methods described herein (i.e., the methods described in Section F). Materials and reagents for carrying out these various methods may be provided in the kits to facilitate the execution of the methods.

[0156] The kits provided may contain chemical reagents and other components. Additionally, kits containing the provided lipid nanoparticles, ionizable lipids, and / or pharmaceutical compositions may include, but are not limited to, instructions for use by the kit user. The kits may also be packaged for easy storage and safe transport, for example, as ampoules or other vials packaged in a capped box.

[0157] The provided kit may comprise one or more containers, each of which is separated to contain various elements of the lipid nanoparticles (e.g., nucleic acids and individual lipid components within the nanoparticles). In some embodiments, the kit may further comprise an endosome membrane destabilizer (e.g., calcium ions). The kit typically contains the lipid nanoparticle composition of this disclosure, preferably in a dehydrated form, along with instructions on its rehydration and application.

[0158] F. Method

[0159] In other respects, this disclosure provides several methods for preparing and / or using the lipid nanoparticles and vaccines described in Section C, the pharmaceutical compositions described in Section D, and / or the kits described in Section E. The methods disclosed herein benefit from the improved properties of the materials provided, such as properties that facilitate the induction of an immune response in a subject. These improved properties include, for example, stimulating the production of antibodies in a subject.

[0160] 1. Inducing an immune response

[0161] Some methods provided by this disclosure can be used to induce an immune response in a subject. These methods generally involve administering to a subject one or more lipid nanoparticles, one or more vaccines, or one or more pharmaceutical compositions, wherein the lipid nanoparticles and vaccines include those described in Section C, and the pharmaceutical compositions include those described in Section D. In some embodiments, inducing an immune response includes increasing antibody production in the subject. The provided methods can be used to induce an immune response against any of the pathogens described in Section C.5.a.

[0162] The disclosed lipid nanoparticles, vaccines, and pharmaceutical compositions can be administered as a single dose or as multiple doses using the provided methods, for example, by administering two doses at intervals of about one week, about two weeks, about three weeks, about one month, about two months, about three months, about six months, or about 12 months. Other suitable dosing regimens can be determined by a practicing physician. In some embodiments, additional compounds or drugs may be co-administered to the subject. Such compounds or drugs may be co-administered to, for example, alleviate signs or symptoms of disease caused by the treated pathogenic infection, or reduce side effects caused by inducing an immune response.

[0163] The provided lipid nanoparticles, vaccines, and / or pharmaceutical compositions can be administered via any of the generally accepted modes of administration. Thus, administration can be, for example, intramuscular, intradermal, intravenous, topical, subcutaneous, percutaneous, transdermal, oral, intra-articular, parenteral, intra-arterial, intracardiac, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, or by inhalation. In a preferred embodiment, the lipid nanoparticles, vaccines, and / or pharmaceutical compositions are administered intramuscularly or intradermally. In a particularly preferred embodiment, the lipid nanoparticles, vaccines, and / or pharmaceutical compositions are administered intramuscularly.

[0164] In some embodiments, the immune response is assessed by detecting antibodies obtained from the subject, for example using an antigen-binding assay (such as an enzyme-linked immunosorbent assay (ELISA)). In some embodiments, the immune response includes generating antibodies that recognize an antigen, wherein the antigen or a fragment thereof is encoded by a nucleic acid in a lipid nanoparticle or a vaccine. The antigen can be any of the antigens described herein, for example, any of the antigens described in section C.5.a.

[0165] In some embodiments, the immune response induced by the provided method is greater than the immune response induced by a corresponding composition that does indeed include lipid nanoparticles having the formulations described in Section C.

[0166] 2. To prevent or treat diseases or symptoms

[0167] Some methods provided by this disclosure can be used to prevent or treat a disease or condition in a subject. These methods generally involve administering to the subject one or more lipid nanoparticles, one or more vaccines, or one or more pharmaceutical compositions, wherein the lipid nanoparticles and vaccines include those described in Section C, and the pharmaceutical compositions include those described in Section D. In some embodiments, treating a subject's disease includes reducing or eliminating one or more signs or symptoms of the disease.

[0168] Typically, the methods provided can be used to prevent or treat infections or infectious diseases caused by pathogens such as viruses, bacteria, fungi, parasites, or any other infectious agents. Non-limiting examples of infectious diseases for which the provided methods may be used for treatment include acquired immunodeficiency syndrome (AIDS / HIV) or HIV-related conditions, Alpers syndrome, anthrax, bovine spongiform encephalopathy (mad cow disease), varicella, cholera, conjunctivitis, Creutzfeldt-Jakob disease (CJD), dengue fever, Ebola, elephantiasis, encephalitis, fatal familial insomnia, Fifth's disease, Gerstmann-Straussler-Scheinker syndrome, hantavirus, Helicobacter pylori, hepatitis (hepatitis A, hepatitis B, hepatitis C), herpes, influenza (e.g., avian influenza A), kuru, leprosy, Lyme disease, malaria, and hemorrhagic fever (e.g., Rift Valley fever). Fever, Crimean-Congo hemorrhagic fever, Lassa fever, Marburg virus disease and Ebola hemorrhagic fever, measles, meningitis (viral and bacterial), mononucleosis, hospital-acquired infections, otitis media, pelvic inflammatory disease (PID), plague, pneumonia, poliomyelitis, prions, rabies, rheumatic fever, roseola, Ross River virus infection, rubella, salmonellosis, pyogenic arthritis, sexually transmitted diseases (STDs), herpes zoster, smallpox, streptococcal pharyngitis, tetanus, toxic shock syndrome, toxoplasmosis, trachoma, tuberculosis, tularemia, typhoid fever, grain fever, pertussis and yellow fever. The methods provided can be used for the prevention or treatment of infections caused by any of the pathogens described in section C.5.a.

[0169] In some embodiments, the provided method further includes obtaining a test sample from a subject. The test sample may include, for example, a blood sample, a tissue sample, a urine sample, a saliva sample, a cerebrospinal fluid sample, or a combination thereof. In some embodiments, the provided method further includes determining the level of one or more biomarkers in the obtained test sample. As a non-limiting example, determining the presence or level of a biomarker may be used to determine a response to treatment or to select an appropriate composition for the prevention or treatment of a disease.

[0170] In instances where the lipid nanoparticles, vaccines, or pharmaceutical compositions provided therein comprise nucleic acids encoding a protein of interest or a fragment thereof, the measured biomarker may be an indicator of the expression level of a protein or fragment in a target cell or target organism (e.g., the cell or organism to which the lipid nanoparticles, vaccine, or pharmaceutical composition is administered). For example, the biomarker may be the protein or fragment itself, such that the measured level of the protein or fragment indicates its expression level. When the protein of interest is an antigen, the measured biomarker may include or be composed of one or more components of the immune system of the target cell or target organism. For example, the biomarker may include or be composed of one or more antibodies or other immunoglobulins. In these ways, the determination of biomarker levels in a test sample can provide information related to the efficiency and / or effectiveness of the administration of lipid nanoparticles in the prevention or treatment of a disease or condition. Example 3 demonstrates the quantification of IgG antibodies as a biomarker after administration of lipid nanoparticles encapsulating nucleic acids (i.e., mRNA) encoding an antigen (i.e., hemagglutinin).

[0171] In some embodiments, the provided method further includes comparing determined levels of one or more biomarkers in the obtained test sample with levels of one or more biomarkers in a reference sample. The reference sample may be obtained, for example, from the subject, wherein the reference sample is obtained prior to obtaining the test sample, e.g., prior to administering a therapeutically effective amount of the provided material to the subject. In this way, the reference sample can provide information about baseline levels of biomarkers in the pre-treatment sample, and the test sample can provide information about post-treatment levels of biomarkers.

[0172] Alternatively, reference samples can be obtained, for example, from different subjects, such as subjects who were not treated according to the provided method. In this way, reference samples can provide information about baseline levels of the biomarker in the absence of treatment, and test samples can provide information about the levels of the biomarker in the presence of treatment. Reference samples can also be obtained, for example, from a group of subjects, such as subjects who were not treated according to the provided method. In this way, reference samples can provide population-average information about baseline levels of the biomarker in the absence of treatment, and test samples can provide information about the levels of the biomarker in the presence of treatment.

[0173] Reference samples may also be obtained from individuals or groups of individuals after treatment has been administered according to the provided method, and may serve as, for example, a positive control sample. In some embodiments, reference samples are obtained from normal tissue. In some embodiments, reference samples are obtained from abnormal tissue.

[0174] An increase or decrease in a biomarker relative to a normal control or reference sample can indicate the presence of a disease or a response to treatment. In some embodiments, an increase in the level of a biomarker in a test sample is determined when the biomarker level is at least 1.1 times higher than a control, for example, at least 1.2 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, at least 13 times, at least 14 times, at least 15 times, at least 16 times, at least 17 times, at least 18 times, at least 19 times, or at least 20 times higher than a control, and thus the presence of a disease (e.g., an infectious disease or cancer), an increased risk of disease, or a response to treatment is determined. In other embodiments, a reduction in the level of a biomarker in the test sample is determined when the biomarker level is at least 1.1 times lower than that of a control, for example, at least 1.2 times, at least 1.3 times, at least 1.4 times, at least 1.5 times, at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, at least 13 times, at least 14 times, at least 15 times, at least 16 times, at least 17 times, at least 18 times, at least 19 times, or at least 20 times lower, and thus the presence of disease, an increased risk of disease, or a response to treatment is determined.

[0175] Biomarker levels can be detected using any method known in the art, including the use of antibodies specific to the biomarker. Exemplary methods include, but are not limited to, polymerase chain reaction (PCR), Western blotting, dot blotting, ELISA, radioimmunoassay (RIA), immunoprecipitation, immunofluorescence, FACS analysis, electrochemiluminescence, and multiplex bead assays (e.g., using Luminex or fluorescent microbeads). In some cases, nucleic acid sequencing is employed.

[0176] In some embodiments, the presence of a reduced or increased level of one or more biomarkers is indicated by a detectable signal (e.g., blot, fluorescence, chemiluminescence, color, or radioactivity) in an immunoassay or PCR reaction (e.g., quantitative PCR). This detectable signal can be compared to a signal or threshold from a reference sample.

[0177] In some embodiments, the results of biomarker level determination are recorded in a tangible medium. For example, the results of diagnostic assays, such as the presence or absence of one or more biomarkers or observations of a decrease or increase in their presence, the presence of an increased risk or disease (e.g., an infectious disease or cancer), or a diagnosis of whether a subject responds to treatment, may be recorded on, for example, paper or electronic media, such as audio tapes, computer disks, CD-ROMs, or flash drives.

[0178] In some embodiments, the provided method further includes the step of providing the subject with diagnostic and / or treatment results.

[0179] 3. Preparation of lipid nanoparticles

[0180] Some methods provided in this disclosure can be used to prepare one or more lipid nanoparticles, wherein the lipid nanoparticles include those described in Section C. Lipid nanoparticles can be prepared by, for example, sequential mixing methods and / or direct dilution methods. In some embodiments, the methods include selecting, designing, and / or preparing one or more components of the prepared lipid nanoparticles. For example, the methods may include selecting, designing, and / or preparing phospholipids, ionizable lipids, cholesterol, or derivatives thereof, conjugated lipids, and / or nucleic acids.

[0181] In some embodiments, the lipid nanoparticles described herein are produced by a continuous mixing method, such as a method comprising: providing an aqueous solution containing a nucleic acid (e.g., any of the nucleic acids described in Section C.5) in a first reservoir, providing an organic lipid solution in a second reservoir, and mixing the aqueous solution with the organic lipid solution such that the organic lipid solution is mixed with the aqueous solution, thereby substantially instantaneously producing lipid particles encapsulating the nucleic acid. Examples of this method and apparatus for carrying out this method are described in U.S. Patent Application Publication No. 2004 / 0142025.

[0182] In some instances, the organic lipid solution is an alcoholic organic solvent comprising an alcoholic solution of lipids that will form lipid nanoparticles. These lipids may include one or more conjugated lipids, one or more ionizable lipids or pharmaceutically acceptable salts thereof, one or more sterols or derivatives thereof, and one or more phospholipids or pharmaceutically acceptable salts thereof. For example, the conjugated lipid may be any of the conjugated lipids described in Section C.1, the ionizable lipid may be any of the ionizable lipids described in Section C.2, the sterol may be any of the cholesterol or derivatives thereof described in Section C.3, and the phospholipid may be any of the phospholipids described in Section C.4. In some embodiments, the alcoholic organic solvent of the alcoholic solution comprises or is composed of ethanol. In some instances, the alcoholic solution is a product of combining an alcoholic organic solvent and a phospholipid solution, wherein the phospholipid solution comprises a non-alcoholic organic solvent and one or more phospholipids or pharmaceutically acceptable salts thereof. In some embodiments, the non-alcoholic organic solvent comprises or is composed of tetrahydrofuran.

[0183] The act of continuously introducing lipids and a buffer solution into a mixing environment (e.g., in a mixing chamber) causes the lipid solution to be continuously diluted with the buffer solution, thereby generating lipid particles essentially immediately upon mixing. As used herein, the phrase “continuously diluting a lipid solution with a buffer solution” (and its variations) generally refers to a lipid solution being diluted sufficiently rapidly and forcefully during hydration to achieve vesicle generation. By mixing an aqueous solution containing nucleic acids with an organic lipid solution, the organic lipid solution undergoes continuous stepwise dilution in the presence of a buffer solution (i.e., an aqueous solution) to generate lipid particles.

[0184] The lipid nanoparticles formed using a continuous mixing method are typically about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 60 nm to about 100 nm, about 50 nm to about 80 nm, about 60 nm to about 80 nm, about 60 nm to about 90 nm, or about 70 nm to about 90 nm. The resulting particles do not aggregate, and the size is optionally set to achieve a uniform particle size.

[0185] In some embodiments, the lipid nanoparticles described herein are produced by a direct dilution method comprising forming a lipid particle solution and immediately and directly introducing the lipid particle solution into a collection container containing a controlled amount of dilution buffer. In some embodiments, the collection container includes one or more elements configured to agitate the contents of the collection container to facilitate dilution. In one embodiment, the amount of dilution buffer present in the collection container is substantially equal to the volume of the lipid particle solution introduced therein. As a non-limiting example, introducing a lipid particle solution containing 45% ethanol into a collection container containing an equal volume of dilution buffer will advantageously produce smaller particles.

[0186] In some embodiments, the lipid nanoparticles described herein are produced via a direct dilution method, wherein a third reservoir containing a dilution buffer is fluidly coupled to a second mixing region. In this embodiment, the lipid particle solution formed in the first mixing region is immediately and directly mixed with the dilution buffer in the second mixing region. In some embodiments, the second mixing region includes a T-connector arranged such that the lipid particle solution and the dilution buffer flow meet as opposing 180° flows; however, connectors providing a shallower angle, for example, about 27° to about 180°, may be used. A pump mechanism delivers a controlled flow of buffer to the second mixing region. In one embodiment, the flow rate of the dilution buffer provided to the second mixing region is controlled to be substantially equal to the flow rate of the lipid particle solution introduced therein from the first mixing region. This embodiment advantageously allows for greater control over the flow of the dilution buffer mixed with the lipid particle solution in the second mixing region, and therefore also allows for greater control over the concentration of the lipid particle solution in the buffer throughout the second mixing process. This control over the dilution buffer flow rate advantageously allows for the formation of smaller particle sizes at reduced concentrations. Examples of these methods and apparatuses for implementing these direct dilution methods are described in U.S. Patent No. 9,005,654.

[0187] The lipid particles formed using the direct dilution method are typically about 40 nm to about 150 nm, about 50 nm to about 150 nm, about 60 nm to about 130 nm, about 70 nm to about 110 nm, about 60 nm to about 100 nm, about 50 nm to about 80 nm, about 60 nm to about 80 nm, about 60 nm to about 90 nm, or about 70 nm to about 90 nm. The resulting particles do not aggregate, and the size is optionally set to achieve a uniform particle size.

[0188] If desired, the lipid particles described herein can be sizing using any of the methods available to those skilled in the art. Sizing can be performed to achieve a desired particle size range and a relatively narrow particle size distribution. Several techniques can be used to sizing the particle size to the desired size, for example, as described in Lam et al. 2023, *Advanced Materials*, 35:26, 2211420. One sizing method for liposomes and equally applicable to the particles of this invention is described in U.S. Patent No. 4,737,323. Sonicating the particle suspension by bath or probe sonication produces a progressive size reduction to a particle size of less than about 50 nm. Homogenization is another method that relies on shear energy to break larger particles into smaller ones. In a typical homogenization procedure, the particles are recycled through a standard emulsion homogenizer until a selected particle size is observed, typically between about 60 nm and about 80 nm. In both methods, the particle size distribution can be monitored using conventional laser beam particle size discrimination or QELS.

[0189] Extruding particles through a microporous polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing particle size to a relatively well-defined size distribution. Typically, the suspension is circulated through the membrane one or more times until the desired particle size distribution is achieved. Particles can be extruded through membranes with progressively smaller pores to achieve a gradual reduction in size.

[0190] In some embodiments, the nucleic acid to lipid ratio (mass / mass ratio) in the formed lipid particles is in the range of about 0.01 to about 0.2, about 0.02 to about 0.1, about 0.03 to about 0.1, or about 0.01 to about 0.08. The ratio of starting materials may also fall within this range. In other embodiments, the lipid particle formulation uses a nucleic acid to lipid mass ratio of about 400 µg nucleic acid / 10 mg total lipids or about 0.01 to about 0.08 (e.g., about 0.04, which corresponds to 1.25 mg total lipids / 50 µg nucleic acid). In some embodiments, the nucleic acid:lipid mass ratio of the particles is about 0.08.

[0191] In other embodiments, the lipid-to-nucleic acid ratio (mass / mass ratio) in the formed lipid particles ranges from about 1 (1:1) to about 100 (100:1), about 5 (5:1) to about 100 (100:1), about 1 (1:1) to about 50 (50:1), about 2 (2:1) to about 50 (50:1), about 3 (3:1) to about 50 (50:1), about 4 (4:1) to about 50 (50:1), about 5 (5:1) to about 50 (50:1), about 1 (1:1) to about 25 (25:1), about 2 (2:1) to about 25 (25:1). 1) Approximately 3 (3:1) to approximately 25 (25:1), approximately 4 (4:1) to approximately 25 (25:1), approximately 5 (5:1) to approximately 25 (25:1), approximately 5 (5:1) to approximately 20 (20:1), approximately 5 (5:1) to approximately 15 (15:1), approximately 5 (5:1) to approximately 10 (10:1), approximately 5 (5:1), 6 (6:1), 7 (7:1), 8 (8:1), 9 (9:1), 10 (10:1), 11 (11:1), 12 (12:1), 13 (13:1), 14 (14:1), or 15 (15:1). The ratio of starting materials may also fall within this range.

[0192] G. Exemplary Embodiment

[0193] The following embodiments are envisioned. All combinations of features and embodiments are envisioned.

[0194] Example 1: A lipid nanoparticle comprising: a conjugated lipid, wherein the conjugated lipid constitutes no more than X mol% of the total lipids of the lipid nanoparticle, and X is not more than 1; a phospholipid or a pharmaceutically acceptable salt thereof, wherein the phospholipid has a net neutral charge at physiological pH; an ionizable lipid or a pharmaceutically acceptable salt thereof; cholesterol or a derivative thereof; and a nucleic acid encoding a protein of interest or a fragment thereof; wherein the composition of the lipid nanoparticle satisfies at least one of the following conditions: (a) the ionizable lipid or its pharmaceutically acceptable salt constitutes at least Y mol% of the total lipids of the lipid nanoparticle, and the value of Y is defined by the following formula: 51.1 - 5.7X + 8.0X 2 (b) The cholesterol or its derivatives constitute no more than Z mol% of the total lipids in the nanoparticles, where Z is defined by the following formula: 39.3 + 2.3X - 5.6X 2 .

[0195] Example 2: According to the example described in Example 1, wherein: (a) the ionizable lipid or its pharmaceutically acceptable salt accounts for at least Y mol% of the total lipids of the nanoparticles; and (b) the cholesterol or its derivative accounts for no more than Z mol% of the total lipids of the nanoparticles.

[0196] Example 3: According to the embodiment described in Example 1 or 2, the ionizable lipid comprises three or more terminal hydrocarbon chains, each of which has five or more members.

[0197] Example 4: According to the example described in Example 3, the ionizable lipid comprises 5-(dimethylamino)valerate (6Z,16Z)-12-((Z)-dec-4-en-1-yl) dodec-6,16-dien-11-yl ester (3D-P-DMA).

[0198] Example 5: According to the example described in Example 1 or 2, the ionizable lipid comprises 4-(dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-heptadec-6,9,28,31-tetraen-19-yl ester (MC3).

[0199] Example 6: An example according to any one of Examples 1 to 5, wherein the value of X is at least 0.5.

[0200] Example 7: According to any one of Examples 1 to 6, the conjugated lipid comprises two or more terminal hydrocarbon chains, each of which has five or more members and is not directly bonded to an ester.

[0201] Example 8: An example according to any one of Examples 1 to 7, wherein the conjugated lipid comprises a carbamate bond.

[0202] Example 9: According to any one of Examples 1 to 8, the conjugated lipid comprises a polyethylene glycol (PEG) lipid conjugate.

[0203] Example 10: According to any one of Examples 1 to 9, the conjugated lipid comprises N-[(methoxypoly(ethylene glycol))carbamoyl]-1,2-dimyristyloxypropylamine (PEG-c-DMA).

[0204] Example 11: An example according to any one of Examples 1 to 10, wherein the phospholipid comprises phosphatidylcholine.

[0205] Example 12: According to the embodiment described in Example 11, wherein the phosphatidylcholine comprises 1,2-distearyl-sn-glycerol-3-phosphate choline (DSPC), 1,2-decanoyl-sn-glycerol-3-phosphate choline, 1,2-disunedecyl-sn-glycerol-3-phosphate choline, 1,3-dipalmitoyl-rac-glycerol-2-phosphate choline, and 1,2-dilauroyl-sn-glycerol-3-phosphate choline (DLPC). 1,2-Ditridecanoyl-sn-glycerol-3-phosphate choline, 1,2-dimyristoyl-sn-glycerol-3-phosphate choline (DMPC), 1,2-dipentadecanoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1,2-diheptadecanoyl-sn-glycerol-3-phosphate choline, 1,2-dinonadecanoyl-sn-glycerol-3-phosphate choline, 1,2-di... Arachidoyl-sn-glycerol-3-phosphate choline, 1,2-bisoctadecenoyl-sn-glycerol-3-phosphate choline, 1,2-bis[(8Z)octadecenoyl]-sn-glycerol-3-phosphate choline, 1,2-dimyristenoyl-sn-glycerol-3-phosphate choline, 1,2-ditransmyristenoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline, 1,2-ditranspalmitoyl- sn-glycerol-3-phosphate choline, 1,2-dicarboxyloyl-sn-glycerol-3-phosphate choline, 1,2-dioleoyl-sn-glycerol-3-phosphate choline (DOPC), 1,2-ditransoleoyl-sn-glycerol-3-phosphate choline, 1,2-dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-dilinolenoyl-sn-glycerol-3-phosphate choline, 1,2-bis(eicosenoyl-sn-glycerol-3-phosphate choline), 1,2-Diarachidonic-sn-glycerol-3-phosphate choline, 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate choline, 1-myristoyl-2-palmitoyl-sn-glycerol-3-phosphate choline (MPPC), 1-myristoyl-2-stearoyl-sn-glycerol-3-phosphate choline (MSPC), 1-palmitoyl-2-myristoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-stearoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-oleoyl-glycerol-3-phosphate choline (POPC), 1-palmitoyl-2-linoleoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-arachidonic-sn-glycerol-3-phosphate choline (PAPC) 1-Stearyl-2-myristoyl-sn-glycerol-3-phosphate choline (SMPC), 1-stearoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-oleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-arachidonicoyl-sn-glycerol-3-phosphate choline, 1-oleoyl-2-myristoyl-sn-glycerol-3-phosphate choline (OMPC), 1-oleoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-oleoyl-2-stearoyl-sn-glycerol-3-phosphate choline, 1-(8Z-octadecenoyl)-2-palmitoyl-sn-glycerol-3-phosphate choline, or combinations thereof.

[0206] Example 13: An example according to any one of Examples 1 to 12, wherein the phospholipid comprises phosphatidylethanolamine.

[0207] Example 14: According to the embodiment described in Example 13, wherein the phosphatidylethanolamine comprises 1,2-bis(heptadecanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-decanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilauroyl-sn-glycerol-3-phosphate ethanolamine (DLPE), 1,2-bis(pentadecanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine (DPPE), 1,2- Distearyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dimyristoyl-sn-glycerol-3-phosphate ethanolamine (DMPE), 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), 1,2-ditransoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenic acid-sn-glycerol-3-phosphate ethanolamine 1,2-Didocoshexaenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-disarachidonicyl-sn-glycerol-3-phosphate ethanolamine (DAPE), 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-linoleoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine (POPE), 1-stearoyl-2-oleoyl- sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-arachidonico-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-arachidonico-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine or combinations thereof.

[0208] Example 15: According to any one of Examples 1 to 14, wherein the lipid nanoparticles further comprise permanently charged cationic lipids, wherein the permanently charged cationic lipids account for no more than 10 mol of the total lipids of the lipid nanoparticles.

[0209] Example 16: An example according to any one of Examples 1 to 14, wherein the lipid nanoparticles do not contain permanently charged cationic lipids.

[0210] Example 17: An embodiment according to any one of Examples 1 to 16, wherein: the conjugated lipid accounts for 0.6 mol% to 1 mol% of the total lipids of the lipid nanoparticles; the phospholipid or its pharmaceutically acceptable salt accounts for 8.5 mol% to 11.5 mol% of the total lipids of the lipid nanoparticles; the ionizable lipid or its pharmaceutically acceptable salt accounts for 50.5 mol% to 58.5 mol% of the total lipids of the nanoparticles; and the cholesterol or its derivative accounts for 29 mol% to 36 mol% of the total lipids of the nanoparticles.

[0211] Example 18: An embodiment according to any one of Examples 1 to 16, wherein: the conjugated lipid accounts for 0.1 mol% to 0.6 mol% of the total lipids of the lipid nanoparticles; the phospholipid or its pharmaceutically acceptable salt accounts for 8.5 mol% to 11.5 mol% of the total lipids of the lipid nanoparticles; the ionizable lipid or its pharmaceutically acceptable salt accounts for 53.5 mol% to 61.5 mol% of the total lipids of the lipid nanoparticles; and the cholesterol or its derivative accounts for 32 mol% to 39 mol% of the total lipids of the nanoparticles.

[0212] Example 19: An embodiment according to any one of Examples 1 to 18, wherein: the ionizable lipid comprises 3D-P-DMA; the conjugated lipid comprises PEG-c-DMA; and the phospholipid comprises DSPC, MC3, or a combination thereof.

[0213] Example 20: An example according to any one of Examples 1 to 19, wherein the nucleic acid comprises RNA.

[0214] Example 21: According to the embodiment described in Example 20, the RNA comprises mRNA, circRNA, saRNA, or a combination thereof.

[0215] Example 22: An example according to any one of Examples 1 to 19, wherein the nucleic acid comprises DNA.

[0216] Example 23: An example according to any one of Examples 1 to 22, wherein the protein of interest comprises an antigen.

[0217] Example 24: According to the example described in Example 23, wherein the antigen is derived from a pathogen, a pathogenic toxin, or a pathogenic adhesive element.

[0218] Example 25: An example according to any one of Examples 1 to 24, wherein the lipid nanoparticles further comprise a pharmaceutically acceptable excipient.

[0219] Example 26: A method for producing lipid nanoparticles, the method comprising: providing an aqueous solution containing a nucleic acid encoding a protein of interest or a fragment thereof; providing an alcohol solution containing an alcoholic organic solvent, a conjugated lipid, an ionizable lipid or a pharmaceutically acceptable salt thereof, cholesterol or a derivative thereof, and a phospholipid or a pharmaceutically acceptable salt thereof; the phospholipid having a net neutral charge at physiological pH; and combining the aqueous solution and the alcohol solution to produce a lipid nanoparticle solution containing the lipid nanoparticles; wherein the conjugated lipid constitutes no more than X mol% of the total lipids in the alcohol solution, X being no more than 1, and the composition of the alcohol solution satisfies at least one of the following conditions: (a) the ionizable lipid or its pharmaceutically acceptable salt constitutes at least Y mol% of the total lipids in the alcohol solution, the value of Y being defined by the following formula: 51.1 - 5.7X + 8.0X 2 (b) The cholesterol or its derivatives constitute no more than Z mol% of the total lipids in the alcoholic solution, where Z is defined by the following formula: 39.3 + 2.3X - 5.6X 2 .

[0220] Example 27: According to the embodiment described in Example 26, the method further comprises removing at least a portion of the alcohol organic solvent from the lipid nanoparticle solution.

[0221] Example 28: According to the example described in Example 27, wherein removing at least a portion of the alcohol organic solvent comprises dialysis of the lipid nanoparticle solution.

[0222] Example 29: An embodiment according to any one of Examples 26 to 28, wherein the method further comprises concentrating the lipid nanoparticle solution.

[0223] Example 30: According to the example described in Example 29, the concentration of the lipid nanoparticle precursor solution includes centrifuging the lipid nanoparticle solution.

[0224] Example 31: An embodiment according to any one of Examples 26 to 30, wherein the method further comprises filtering the lipid nanoparticle solution.

[0225] Example 32: An example according to any one of Examples 26 to 31, wherein the alcohol organic solvent comprises ethanol.

[0226] Example 33: According to any one of Examples 26 to 32, the provision of the alcohol solution comprises: forming a phospholipid solution comprising a non-alcoholic organic solvent and the phospholipid or a pharmaceutically acceptable salt thereof; and combining the phospholipid solution and the alcoholic organic solvent.

[0227] Example 34: According to the example described in Example 33, the non-alcoholic organic solvent comprises tetrahydrofuran.

[0228] Example 35: An example according to any one of Examples 26 to 34, wherein: (a) the ionizable lipid or its pharmaceutically acceptable salt accounts for at least Y mol% of the total lipids in the alcoholic solution; and (b) the cholesterol or its derivative accounts for no more than Z mol% of the total lipids in the alcoholic solution.

[0229] Example 36: An embodiment according to any one of Examples 26 to 35, wherein the ionizable lipid comprises three or more terminal hydrocarbon chains, each of the three or more terminal hydrocarbon chains having five or more members.

[0230] Example 37: According to the embodiment described in Example 36, the ionizable lipid comprises 3D-P-DMA.

[0231] Example 38: An embodiment according to any one of Examples 26 to 35, wherein the ionizable lipid comprises MC3.

[0232] Example 39: An example according to any one of Examples 26 to 38, wherein the value of X is at least 0.5.

[0233] Example 40: An embodiment according to any one of Examples 26 to 39, wherein the conjugated lipid comprises two or more terminal hydrocarbon chains, each of the two or more terminal hydrocarbon chains having five or more members and each not being directly bonded to an ester.

[0234] Example 41: An example according to any one of Examples 26 to 40, wherein the conjugated lipid comprises a carbamate bond.

[0235] Example 42: An example according to any one of Examples 26 to 41, wherein the conjugated lipid comprises a PEG-lipid conjugate.

[0236] Example 43: An example according to any one of Examples 26 to 42, wherein the conjugated lipid comprises PEG-c-DMA.

[0237] Example 44: An example according to any one of Examples 26 to 43, wherein the phospholipid comprises phosphatidylcholine.

[0238] Example 45: According to the embodiment described in Example 44, wherein the phosphatidylcholine comprises DSPC, 1,2-dicepanoyl-sn-glycerol-3-phosphate choline, 1,2-diundecanoyl-sn-glycerol-3-phosphate choline, 1,3-dipalmitoyl-rac-glycerol-2-phosphate choline, DLPC, 1,2-ditridecanoyl-sn-glycerol-3-phosphate choline, DMPC, 1,2-dipentadecanoyl-sn-glycerol-3-phosphate choline, DPPC, 1,2-diheptadecanoyl-sn-glycerol-3-phosphate choline, 1, 2-Diarachidoyl-sn-glycerol-3-phosphate choline, 1,2-bisoctadecenoyl-sn-glycerol-3-phosphate choline, 1,2-bis[(8Z)octadecenoyl]-sn-glycerol-3-phosphate choline, 1,2-dimyristenoyl-sn-glycerol-3-phosphate choline, 1,2-ditransmyristenoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline, 1,2-ditranspalmitoyl-sn-glycerol-3-phosphate choline, 1,2-dicarboxylic acid-sn-glycerol-3-phosphate choline, DOPC, 1,2-ditransoleoyl-sn-glycerol-3-phosphate choline - Phosphocholine, 1,2-Dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-Dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-biseicosenoyl-sn-glycerol-3-phosphate choline, 1,2-diarachidonicoyl-sn-glycerol-3-phosphate choline, 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate choline, MPPC, MSPC, 1-palmitoyl-2-myristoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-stearoyl-sn-glycerol-3-phosphate choline, POPC, 1-palmitoyl-2-linoleoyl-sn-glycerol- 3-Phosphocholine, PAPC, SMPC, 1-stearoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-oleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-arachidonicoyl-sn-glycerol-3-phosphate choline, OMPC, 1-oleoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-oleoyl-2-stearoyl-sn-glycerol-3-phosphate choline, 1-(8Z-octadecenoyl)-2-palmitoyl-sn-glycerol-3-phosphate choline or combinations thereof.

[0239] Example 46: An example according to any one of Examples 26 to 45, wherein the phospholipid comprises phosphatidylethanolamine.

[0240] Example 47: According to the embodiment described in Example 46, wherein the phosphatidylethanolamine comprises 1,2-diheptadecanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-decanoyl-sn-glycerol-3-phosphate ethanolamine, DLPE, 1,2-dipentadecanoyl-sn-glycerol-3-phosphate ethanolamine, DPPE, 1,2-distearate-sn-glycerol-3-phosphate ethanolamine, DMPE, 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine, DOPE, 1,2-ditransoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-bis(docohexanoyl-s) n-glycerol-3-phosphate ethanolamine, DAPE, 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-linoleoyl-sn-glycerol-3-phosphate ethanolamine, POPE, 1-stearoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-arachidonicoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-arachidonicoyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine, or combinations thereof.

[0241] Example 48: An example according to any one of Examples 26 to 47, wherein the alcohol solution further comprises permanently charged cationic lipids, and the permanently charged cationic lipids account for no more than 10 mol of the total lipids in the alcohol solution.

[0242] Example 49: An example according to any one of Examples 26 to 47, wherein the alcohol solution does not contain permanently charged cationic lipids.

[0243] Example 50: An example according to any one of Examples 26 to 49, wherein: the conjugated lipid accounts for 0.6 mol% to 1 mol% of the total lipids in the alcohol solution; the phospholipid or its pharmaceutically acceptable salt accounts for 8.5 mol% to 11.5 mol% of the total lipids in the alcohol solution; the ionizable lipid or its pharmaceutically acceptable salt accounts for 50.5 mol% to 58.5 mol% of the total lipids in the alcohol solution; and the cholesterol or its derivative accounts for 29 mol% to 36 mol% of the total lipids in the alcohol solution.

[0244] Example 51: An example according to any one of Examples 26 to 49, wherein: the conjugated lipid accounts for 0.1 mol% to 0.6 mol% of the total lipids in the alcohol solution; the phospholipid or its pharmaceutically acceptable salt accounts for 8.5 mol% to 11.5 mol% of the total lipids in the alcohol solution; the ionizable lipid or its pharmaceutically acceptable salt accounts for 53.5 mol% to 61.5 mol% of the total lipids in the alcohol solution; and the cholesterol or its derivative accounts for 32 mol% to 39 mol% of the total lipids in the alcohol solution.

[0245] Example 52: An embodiment according to any one of Examples 26 to 51, wherein: the ionizable lipid comprises 3D-P-DMA; the conjugated lipid comprises PEG-c-DMA; and the phospholipid comprises DSPC, MC3, or a combination thereof.

[0246] Example 53: An example according to any one of Examples 26 to 52, wherein the nucleic acid comprises RNA.

[0247] Example 54: According to the example described in Example 53, the RNA comprises mRNA, circRNA, saRNA, or a combination thereof.

[0248] Example 55: An example according to any one of Examples 26 to 52, wherein the nucleic acid comprises DNA.

[0249] Example 56: An example according to any one of Examples 26 to 55, wherein the protein of interest comprises an antigen.

[0250] Example 57: According to the example described in Example 56, wherein the antigen is derived from a pathogen, a pathogenic toxin, or a pathogenic adhesive element.

[0251] Example 58: A method for inducing an immune response in a subject against the protein of interest of the lipid nanoparticles according to any one of Examples 1 to 25, the method comprising administering a therapeutically effective amount of the lipid nanoparticles to the subject.

[0252] Example 59: According to the example described in Example 58, the immune response includes an increase in antibody production.

[0253] Example 60: An example according to Example 58 or 59, wherein the application is performed intradermally or intramuscularly.

[0254] Example 61: An example according to any one of Examples 1 to 25, used to induce an immune response against the protein of interest of the lipid nanoparticles in a subject.

[0255] Example 62: According to the example described in Example 61, the immune response includes an increase in antibody production.

[0256] Example 63: Use of a lipid nanoparticle according to any one of Examples 1 to 25 for the preparation of a medicament for inducing an immune response against the protein of interest of the lipid nanoparticle in a subject.

[0257] Example 64: According to the example described in Example 63, the immune response includes an increase in antibody production.

[0258] Example 65: A method for preventing or treating a disease in a subject, the method comprising administering to the subject a therapeutically effective amount of lipid nanoparticles according to any one of Examples 1 to 25.

[0259] Example 66: According to the embodiment described in Example 65, the disease includes an infection.

[0260] Example 67: According to the embodiment described in Example 65, wherein the application is performed intradermally or intramuscularly.

[0261] Example 68: An example according to any one of Examples 1 to 25, used for the prevention or treatment of a disease in a subject.

[0262] Example 69: According to the embodiment described in Example 68, the disease includes an infection.

[0263] Example 70: Use of the lipid nanoparticles according to any one of Examples 1 to 25 for the preparation of a medicament for the prevention or treatment of a disease in a subject.

[0264] Example 71: According to the embodiment described in Example 70, the disease includes an infection.

[0265] Example

[0266] This disclosure will be described in more detail through specific examples. The following examples are for illustrative purposes only and are not intended to limit this disclosure in any way.

[0267] Example 1. Preparation of lipid nanoparticles.

[0268] Nucleic acids were encapsulated in LNPs using a controlled mixing method (US 9,005,654), in which an aqueous solution of pH 5.0 mRNA in 100 mM acetate buffer was combined with an ethanol solution of lipids containing PEG-conjugated lipids, ionizable lipids (3D-P-DMA: 5-(dimethylamino)valerate (6Z,16Z)-12-((Z)-dec-4-en-1-yl) docos-6,16-dien-11-yl ester; WO 2013 / 126803), cholesterol, and 1,2-distearyl-sn-glycerol-3-phosphocholine (DSPC) in different molar amounts as outlined in Tables 1 (Example 2), 2 (Example 3), 3 (Example 4), and 4 (Example 5). The ethanol was then removed, and the external buffer was replaced with Tris / NaCl buffer by dialysis. Following dialysis, the formulation was concentrated using a VivaSpin concentrator unit (MWCO 100,000) and filtered through a 0.2 µm sterile filter. Aliquots were then stored frozen at -80°C in Tris-sucrose buffer at pH 8.0. Nucleic acid concentrations were determined using the RiboGreen assay. Particle size and polydispersity were determined using the Malvern Nano Zetasizer series.

[0269] Example 2. Comparison of mRNA-LNP modulators used as vaccines against hemagglutinin.

[0270] A codon-optimized A / Puerto Rico / 8 / 1934 (H1N1) hemagglutinin (HA) (SEQ ID NO. 1) (GenScript) was synthesized and cloned into an mRNA production plasmid. HA mRNA was generated on the linearized plasmid using T7 RNA polymerase (MEGASCRIPT, Ambion). Post-transcriptional, the RNA was enzymatically polyadenylated (NEB). Pseudouridine-5'-triphosphate (TriLink) was used instead of UTP (uridine 5'-triphosphate) to generate HA and mRNA containing the modified nucleoside. The in vitro transcribed mRNA was co-capped using the trinucleotide cap 1 analog CleanCap (TriLink). The mRNA was purified by cellulose purification as previously described (Baiersdörfer et al., Molecular Therapy: Nucleic Acids, 15, (2019): 26).

[0271] Lipid nanoparticles containing HA mRNA were prepared according to Table A. Female Balb / c mice (7-8 weeks old) were immunized against HA protein by intramuscular injection of 10 µg of each LNP formulation (or PBS control). Serum was collected 28 days post-immunization, and the potency of each formulation was determined by ELISA to quantify the amount of IgG antibodies produced against the antigen encoded by mRNA (HA). Briefly, for the anti-HA ELISA, CORNING® 96-well clear flat-bottom polystyrene high-binding microplates (Corning #9018) were coated overnight at 4°C with PBS (100 μL / well) containing 1 μg / ml purified HA (SinoBiological #11684-V08H). The next day, the coated plates were washed three times with washing buffer (PBS containing 0.05% Tween-20). The plate was then blocked with PBS containing 10% FBS at room temperature for 1 hour and washed three times with wash buffer. Mouse serum and anti-HA Ab (Essential Biotech #11684-MM03) used to generate the standard curve were diluted in blocking buffer and incubated at room temperature for 2 hours, followed by three washes. HRP-conjugated anti-mouse secondary antibody (Jackson Immunoresearch #115-036-071) was diluted 1:10,000 in blocking buffer and incubated for 1 hour, followed by three washes. The BD TMB substrate reagent kit (#BDB555214) was applied to the plate, and the reaction was terminated with 2 N sulfuric acid. The absorbance was measured at 450 nm using a Tecan Safire 2 microplate reader.

[0272] Table 1

[0273]

[0274] Example 3. Comparison of mRNA-LNP modulators used as vaccines against ovalbumin.

[0275] Commercially available modified ovalbumin (OVA) mRNA was purchased from Triplex (L-7210, 5 molU). Lipid nanoparticles containing OVA mRNA were prepared according to Table 2. For each test case, female Balb / c mice (7–8 weeks old) were immunized against OVA protein by intramuscular injection of 1 µg of LNP formulation (or PBS control) on days 0 and 21. Serum was collected 14 days after the second immunization, and the potency of each formulation was determined by ELISA to quantify the amount of IgG antibody produced against the antigen encoded by the mRNA (OVA). Serum anti-OVA IgG antibody titers were determined using a commercially available kit (Chondrex, #3011) and according to the manufacturer's instructions.

[0276] Table 2

[0277]

[0278] Example 4. The suitability of low-conjugation lipid formulations for alternative cationic lipid identities.

[0279] HA mRNA was generated as described in Example 2. Lipid nanoparticles containing HA mRNA were prepared according to Table 3. For this example, two different cationic lipids were compared in formulations with different percentages of PEG lipids. Female Balb / c mice (7-8 weeks old) were immunized against HA protein by intramuscular injection of 1 µg or 5 µg of the tested LNP formulation (or PBS control). Serum was collected 28 days post-immunization, and the potency of each formulation was determined by ELISA to quantify the amount of IgG antibodies produced against the antigen encoded by mRNA (HA). ELISA was typically performed as described in Example 2.

[0280] Table 3

[0281]

[0282] Example 5. Applicability of low mol% conjugated lipid formulations to alternative PEG lipids and PEOZ lipids.

[0283] HA mRNA was generated as described in Example 2. Lipid nanoparticles containing HA mRNA were prepared according to Table 4. For this example, different PEG lipids or substitutions with PEOZ lipids were compared with different mol% values. For each test case, female Balb / c mice (7-8 weeks old) were immunized against HA protein by intramuscular injection of 10 µg of LNP formulation (or PBS control). Serum was collected 28 days post-immunization, and the potency of each formulation was determined by ELISA to quantify the amount of IgG antibodies produced against the antigen encoded by mRNA (HA). ELISA was performed as described in Example 2.

[0284] Table 4

[0285]

[0286] Although the foregoing disclosure has been described in detail by way of illustration and example for purposes of clarity, those skilled in the art will understand that certain changes and modifications within the spirit and scope of this disclosure may be practiced, for example, within the scope of the appended claims. It should also be understood that various aspects of this disclosure, as well as portions of the various described embodiments and features, may be combined or interchanged in whole or in part. In the foregoing description of the various embodiments, those embodiments referenced to another embodiment may be suitably combined with other embodiments, as will be understood by those skilled in the art. Furthermore, those skilled in the art will understand that the above description is merely illustrative and not intended to limit the scope of this disclosure. Additionally, each reference provided herein is incorporated herein by reference in its entirety for all purposes, to the same extent that each reference is individually incorporated by reference.

[0287] sequence list

[0288]

Claims

1. A lipid nanoparticle comprising: Conjugated lipids, wherein the conjugated lipids account for no more than X mol% of the total lipids in the lipid nanoparticles, and the value of X is no more than 1; Phospholipids or pharmaceutically acceptable salts thereof, wherein the phospholipids have a net neutral charge at physiological pH; Ionizable lipids or their pharmaceutically acceptable salts; Cholesterol or its derivatives; as well as Nucleic acid, which encodes a protein or fragment thereof of interest; The composition of the lipid nanoparticles satisfies at least one of the following conditions: (a) The ionizable lipid or its pharmaceutically acceptable salt constitutes at least Y mol% of the total lipids in the lipid nanoparticles, where the value of Y is defined by the following formula: 51.1 - 5.7X + 8.0X 2 ; as well as (b) The cholesterol or its derivatives constitute no more than Z mol% of the total lipids in the nanoparticles, where Z is defined by the following formula: 39.3 + 2.3X - 5.6X 2 .

2. The lipid nanoparticles according to claim 1, wherein: (a) The ionizable lipid or its pharmaceutically acceptable salt constitutes at least Y mol% of the total lipids in the nanoparticles; and (b) The cholesterol or its derivatives constitute no more than 2 mol of the total lipids in the nanoparticles.

3. The lipid nanoparticles according to claim 1 or 2, wherein the ionizable lipid comprises three or more terminal hydrocarbon chains, each of the three or more terminal hydrocarbon chains having five or more members.

4. The lipid nanoparticles according to claim 3, wherein the ionizable lipid comprises 5-(dimethylamino)valerate (6Z,16Z)-12-((Z)-dec-4-en-1-yl) dodecano-6,16-dien-11-yl ester (3D-P-DMA).

5. The lipid nanoparticles according to claim 1 or 2, wherein the ionizable lipid comprises 4-(dimethylamino)butyric acid (6Z,9Z,28Z,31Z)-heptadec-6,9,28,31-tetraen-19-yl ester (MC3).

6. The lipid nanoparticles according to any one of claims 1 to 5, wherein the value of X is at least 0.

5.

7. The lipid nanoparticles according to any one of claims 1 to 6, wherein the conjugated lipid comprises two or more terminal hydrocarbon chains, each of the two or more terminal hydrocarbon chains having five or more members and each not being directly bonded to an ester.

8. The lipid nanoparticles according to any one of claims 1 to 7, wherein the conjugated lipid comprises a carbamate bond.

9. The lipid nanoparticles according to any one of claims 1 to 8, wherein the conjugated lipid comprises a polyethylene glycol (PEG) lipid conjugate.

10. The lipid nanoparticles according to any one of claims 1 to 9, wherein the conjugated lipid comprises N-[(methoxypoly(ethylene glycol))carbamoyl]-1,2-dimyristyloxypropylamine (PEG-c-DMA).

11. The lipid nanoparticles according to any one of claims 1 to 10, wherein the phospholipid comprises phosphatidylcholine.

12. The lipid nanoparticles of claim 11, wherein the phosphatidylcholine comprises 1,2-distearyl-sn-glycerol-3-phosphate choline (DSPC), 1,2-decanoyl-sn-glycerol-3-phosphate choline, 1,2-disunedecanoyl-sn-glycerol-3-phosphate choline, 1,3-dipalmitoyl-rac-glycerol-2-phosphate choline, and 1,2-dilauroyl-sn-glycerol-3-phosphate choline (DLPC). 1,2-Ditridecanoyl-sn-glycerol-3-phosphate choline, 1,2-Dimyristoyl-sn-glycerol-3-phosphate choline (DMPC), 1,2-Dipentadecanoyl-sn-glycerol-3-phosphate choline, 1,2-Dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1,2-Diheptadecanoyl-sn-glycerol-3-phosphate choline, 1,2-Dinonadecanoyl-sn-glycerol-3-phosphate choline, 1,2- Diarachidoyl-sn-glycerol-3-phosphate choline, 1,2-bisoctadecenoyl-sn-glycerol-3-phosphate choline, 1,2-bis[(8Z)octadecenoyl]-sn-glycerol-3-phosphate choline, 1,2-dimyristenoyl-sn-glycerol-3-phosphate choline, 1,2-ditransmyristenoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline, 1,2-ditranspalmitoyl- sn-glycerol-3-phosphate choline, 1,2-dicarboxyloyl-sn-glycerol-3-phosphate choline, 1,2-dioleoyl-sn-glycerol-3-phosphate choline (DOPC), 1,2-ditransoleoyl-sn-glycerol-3-phosphate choline, 1,2-dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-dilinolenoyl-sn-glycerol-3-phosphate choline, 1,2-bis(eicosenoyl-sn-glycerol-3-phosphate choline), 1,2-Diarachidonic-sn-glycerol-3-phosphate choline, 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate choline, 1-myristoyl-2-palmitoyl-sn-glycerol-3-phosphate choline (MPPC), 1-myristoyl-2-stearoyl-sn-glycerol-3-phosphate choline (MSPC), 1-palmitoyl-2-myristoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-stearoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-oleoyl-glycerol-3-phosphate choline (POPC), 1-palmitoyl-2-linoleoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-arachidonic-sn-glycerol-3-phosphate choline (PAPC) 1-Stearyl-2-myristoyl-sn-glycerol-3-phosphate choline (SMPC), 1-stearoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-oleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-arachidonicoyl-sn-glycerol-3-phosphate choline, 1-oleoyl-2-myristoyl-sn-glycerol-3-phosphate choline (OMPC), 1-oleoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-oleoyl-2-stearoyl-sn-glycerol-3-phosphate choline, 1-(8Z-octadecenoyl)-2-palmitoyl-sn-glycerol-3-phosphate choline, or combinations thereof.

13. The lipid nanoparticles according to any one of claims 1 to 12, wherein the phospholipid comprises phosphatidylethanolamine.

14. The lipid nanoparticles of claim 13, wherein the phosphatidylethanolamine comprises 1,2-bis(heptadecanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-decanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilauroyl-sn-glycerol-3-phosphate ethanolamine (DLPE), 1,2-bis(pentadecanoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine (DPPE), 1,2 Distearatel-sn-glycerol-3-phosphate ethanolamine, 1,2-dimyristoyl-sn-glycerol-3-phosphate ethanolamine (DMPE), 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), 1,2-ditransoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine 3-Phosphoethanolamine, 1,2-bis(docosahexaenoyl-sn-glycerol-3-phosphate ethanolamine), 1,2-disarachidonicyl-sn-glycerol-3-phosphate ethanolamine (DAPE), 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-linoleoyl-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate ethanolamine (POPE), 1-stearoyl-2-oleoyl- sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-arachidonico-sn-glycerol-3-phosphate ethanolamine, 1-palmitoyl-2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-arachidonico-sn-glycerol-3-phosphate ethanolamine, 1-stearoyl-2-docosahexaenooyl-sn-glycerol-3-phosphate ethanolamine or combinations thereof.

15. The lipid nanoparticles according to any one of claims 1 to 14, wherein the lipid nanoparticles further comprise permanently charged cationic lipids, the permanently charged cationic lipids comprising no more than 10 mol of the total lipids of the lipid nanoparticles.

16. The lipid nanoparticles according to any one of claims 1 to 14, wherein the lipid nanoparticles do not contain permanently charged cationic lipids.

17. The lipid nanoparticles according to any one of claims 1 to 16, wherein: The conjugated lipids comprise 0.6 mol% to 1 mol% of the total lipids in the lipid nanoparticles. The phospholipid or its pharmaceutically acceptable salt constitutes 8.5 mol% to 11.5 mol% of the total lipids in the lipid nanoparticles. The ionizable lipids or their pharmaceutically acceptable salts comprise 50.5 mol% to 58.5 mol% of the total lipids in the nanoparticles; and The cholesterol or its derivatives comprise 29 mol% to 36 mol% of the total lipids in the nanoparticles.

18. The lipid nanoparticles according to any one of claims 1 to 16, wherein: The conjugated lipids comprise 0.1 mol% to 0.6 mol% of the total lipids in the lipid nanoparticles. The phospholipid or its pharmaceutically acceptable salt constitutes 8.5 mol% to 11.5 mol% of the total lipids in the lipid nanoparticles. The ionizable lipid or its pharmaceutically acceptable salt constitutes 53.5 mol% to 61.5 mol% of the total lipids in the lipid nanoparticles; and The cholesterol or its derivatives comprise 32 mol% to 39 mol% of the total lipids in the nanoparticles.

19. The lipid nanoparticles according to any one of claims 1 to 18, wherein: The ionizable lipid contains 3D-P-DMA; The conjugated lipid comprises PEG-c-DMA; and The phospholipids include DSPC, MC3, or a combination thereof.

20. The lipid nanoparticles according to any one of claims 1 to 19, wherein the nucleic acid comprises RNA.

21. The lipid nanoparticle of claim 20, wherein the RNA comprises mRNA, circRNA, saRNA, or a combination thereof.

22. The lipid nanoparticles according to any one of claims 1 to 19, wherein the nucleic acid comprises DNA.

23. The lipid nanoparticles according to any one of claims 1 to 22, wherein the protein of interest comprises an antigen.

24. The lipid nanoparticles of claim 23, wherein the antigen is derived from a pathogen, a pathogenic toxin, or a pathogenic adhesion element.

25. The lipid nanoparticles according to any one of claims 1 to 24, wherein the lipid nanoparticles further comprise a pharmaceutically acceptable excipient.

26. A method for producing lipid nanoparticles, the method comprising: Provide an aqueous solution containing nucleic acids, said nucleic acids encoding the protein of interest or a fragment thereof; An alcohol solution is provided, the alcohol solution comprising an alcohol organic solvent, a conjugated lipid, an ionizable lipid or a pharmaceutically acceptable salt thereof, cholesterol or a derivative thereof, and a phospholipid or a pharmaceutically acceptable salt thereof; The phospholipids have a net neutral charge at physiological pH. as well as The aqueous solution and the alcohol solution are combined to produce a lipid nanoparticle solution containing the lipid nanoparticles; The conjugated lipids constitute no more than X mol% of the total lipids in the alcohol solution, where X is no more than 1, and the composition of the alcohol solution satisfies at least one of the following conditions: (a) The ionizable lipid or its pharmaceutically acceptable salt constitutes at least Y mol% of the total lipids in the alcoholic solution, where the value of Y is defined by the following formula: 51.1 - 5.7X + 8.0X 2 ; as well as (b) The cholesterol or its derivatives constitute no more than Z mol% of the total lipids in the alcoholic solution, where Z is defined by the following formula: 39.3 + 2.3X - 5.6X 2 .

27. The method of claim 26, wherein the method further comprises removing at least a portion of the alcohol organic solvent from the lipid nanoparticle solution.

28. The method of claim 27, wherein removing at least a portion of the alcoholic organic solvent comprises dialysis of the lipid nanoparticle solution.

29. The method according to any one of claims 26 to 28, wherein the method further comprises concentrating the lipid nanoparticle solution.

30. The method of claim 29, wherein the concentration of the lipid nanoparticle precursor solution comprises centrifuging the lipid nanoparticle solution.

31. The method according to any one of claims 26 to 30, wherein the method further comprises filtering the lipid nanoparticle solution.

32. The method according to any one of claims 26 to 31, wherein the alcohol organic solvent comprises ethanol.

33. The method according to any one of claims 26 to 32, wherein the provision of the alcohol solution comprises: To form a phospholipid solution comprising a non-alcoholic organic solvent and the phospholipid or a pharmaceutically acceptable salt thereof; and The phospholipid solution and the alcohol organic solvent are combined.

34. The method of claim 33, wherein the non-alcoholic organic solvent comprises tetrahydrofuran.

35. The method according to any one of claims 26 to 34, wherein: (a) The ionizable lipid or its pharmaceutically acceptable salt constitutes at least Y mol% of the total lipids in the alcoholic solution; and (b) The cholesterol or its derivatives constitute no more than 2 mol% of the total lipids in the alcoholic solution.

36. The method according to any one of claims 26 to 35, wherein the ionizable lipid comprises three or more terminal hydrocarbon chains, each of the three or more terminal hydrocarbon chains having five or more members.

37. The method of claim 36, wherein the ionizable lipid comprises 3D-P-DMA.

38. The method according to any one of claims 26 to 35, wherein the ionizable lipid comprises MC3.

39. The method according to any one of claims 26 to 38, wherein the value of X is at least 0.

5.

40. The method according to any one of claims 26 to 39, wherein the conjugated lipid comprises two or more terminal hydrocarbon chains, each of the two or more terminal hydrocarbon chains having five or more members and each not being directly bonded to an ester.

41. The method according to any one of claims 26 to 40, wherein the conjugated lipid comprises a carbamate bond.

42. The method according to any one of claims 26 to 41, wherein the conjugated lipid comprises a PEG-lipid conjugate.

43. The method according to any one of claims 26 to 42, wherein the conjugated lipid comprises PEG-c-DMA.

44. The method according to any one of claims 26 to 43, wherein the phospholipid comprises phosphatidylcholine.

45. The method of claim 44, wherein the phosphatidylcholine comprises DSPC, 1,2-dicepanoyl-sn-glycerol-3-phosphate choline, 1,2-diundecanoyl-sn-glycerol-3-phosphate choline, 1,3-dipalmitoyl-rac-glycerol-2-phosphate choline, DLPC, 1,2-ditridecanoyl-sn-glycerol-3-phosphate choline, DMPC, 1,2-dipentadecanoyl-sn-glycerol-3-phosphate choline, DPPC, 1,2-diheptadecanoyl-sn-glycerol-3-phosphate choline, 1,2-dinonadecanoyl-sn-glycerol-3-phosphate choline, 1,2- Arachinoyl-sn-glycerol-3-phosphate choline, 1,2-bis(8Z)octadecenoyl]-sn-glycerol-3-phosphate choline, 1,2-di-myristenoyl-sn-glycerol-3-phosphate choline, 1,2-ditransmyristenoyl-sn-glycerol-3-phosphate choline, 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline, 1,2-ditranspalmitoyl-sn-glycerol-3-phosphate choline, 1,2-di-caryopicrinoyl-sn-glycerol-3-phosphate choline, DOPC, 1,2-ditransoleoyl-sn-glycerol-3-phosphate choline Phosphocholine, 1,2-Dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-Dilinoleoyl-sn-glycerol-3-phosphate choline, 1,2-biseicosenoyl-sn-glycerol-3-phosphate choline, 1,2-diarachidonicoyl-sn-glycerol-3-phosphate choline, 1-pentadecanoyl-2-oleoyl-sn-glycerol-3-phosphate choline, MPPC, MSPC, 1-palmitoyl-2-myristoyl-sn-glycerol-3-phosphate choline, 1-palmitoyl-2-stearoyl-sn-glycerol-3-phosphate choline, POPC, 1-palmitoyl-2-linoleoyl-sn-glycerol-3-phosphate choline - Phosphocholine, PAPC, SMPC, 1-stearoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-oleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphate choline, 1-stearoyl-2-arachidonicoyl-sn-glycerol-3-phosphate choline, OMPC, 1-oleoyl-2-palmitoyl-sn-glycerol-3-phosphate choline, 1-oleoyl-2-stearoyl-sn-glycerol-3-phosphate choline, 1-(8Z-octadecenoyl)-2-palmitoyl-sn-glycerol-3-phosphate choline or combinations thereof.

46. ​​The method according to any one of claims 26 to 45, wherein the phospholipid comprises phosphatidylethanolamine.

47. The method of claim 46, wherein the phosphatidylethanolamine comprises 1,2-diheptadecanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-decanoyl-sn-glycerol-3-phosphate ethanolamine, DLPE, 1,2-dipentadecanoyl-sn-glycerol-3-phosphate ethanolamine, DPPE, 1,2-distearate-sn-glycerol-3-phosphate ethanolamine, DMPE, 1,2-dipalmitoyl-sn-glycerol-3-phosphate ethanolamine, DOPE, 1,2-ditransoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinolenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dicarboxyhexaenoyl-sn- Glyceryl-3-phosphate ethanolamine, DAPE, 1-pentadecanoyl-2-oleoyl-sn-glyceryl-3-phosphate ethanolamine, 1-palmitoyl-2-linoleoyl-sn-glyceryl-3-phosphate ethanolamine, POPE, 1-stearoyl-2-oleoyl-sn-glyceryl-3-phosphate ethanolamine, 1-palmitoyl-2-arachidonicoyl-sn-glyceryl-3-phosphate ethanolamine, 1-palmitoyl-2-docosahexaenooyl-sn-glyceryl-3-phosphate ethanolamine, 1-stearoyl-2-linoleoyl-sn-glyceryl-3-phosphate ethanolamine, 1-stearoyl-2-arachidonicoyl-sn-glyceryl-3-phosphate ethanolamine, 1-stearoyl-2-docosahexaenooyl-sn-glyceryl-3-phosphate ethanolamine, or combinations thereof.

48. The method according to any one of claims 26 to 47, wherein the alcohol solution further comprises a permanently charged cationic lipid, and the permanently charged cationic lipid accounts for no more than 10 mol of the total lipids in the alcohol solution.

49. The method according to any one of claims 26 to 47, wherein the alcohol solution does not contain permanently charged cationic lipids.

50. The method according to any one of claims 26 to 49, wherein: The conjugated lipids comprise 0.6 mol% to 1 mol% of the total lipids in the alcohol solution. The phospholipid or its pharmaceutically acceptable salt constitutes 8.5 mol% to 11.5 mol% of the total lipids in the alcoholic solution. The ionizable lipid or its pharmaceutically acceptable salt constitutes 50.5 mol% to 58.5 mol% of the total lipids in the alcoholic solution; and The cholesterol or its derivatives comprise 29 mol% to 36 mol% of the total lipids in the alcohol solution.

51. The method according to any one of claims 26 to 49, wherein: The conjugated lipids comprise 0.1 mol% to 0.6 mol% of the total lipids in the alcohol solution. The phospholipid or its pharmaceutically acceptable salt constitutes 8.5 mol% to 11.5 mol% of the total lipids in the alcoholic solution. The ionizable lipid or its pharmaceutically acceptable salt constitutes 53.5 mol% to 61.5 mol% of the total lipids in the alcoholic solution; and The cholesterol or its derivatives comprise 32 mol% to 39 mol% of the total lipids in the alcohol solution.

52. The method according to any one of claims 26 to 51, wherein: The ionizable lipid contains 3D-P-DMA; The conjugated lipid comprises PEG-c-DMA; and The phospholipids include DSPC, MC3, or a combination thereof.

53. The method according to any one of claims 26 to 52, wherein the nucleic acid comprises RNA.

54. The method of claim 53, wherein the RNA comprises mRNA, circRNA, saRNA, or a combination thereof.

55. The method according to any one of claims 26 to 52, wherein the nucleic acid comprises DNA.

56. The method according to any one of claims 26 to 55, wherein the protein of interest comprises an antigen.

57. The method according to any one of claims 56, wherein the antigen is derived from a pathogen, a pathogenic toxin, or a pathogenic adhesive element.

58. A method for inducing an immune response in a subject against the protein of interest of a lipid nanoparticle according to any one of claims 1 to 25, the method comprising administering a therapeutically effective amount of the lipid nanoparticle to the subject.

59. The method of claim 58, wherein the immune response comprises an increase in antibody production.

60. The method of claim 58 or 59, wherein the application is performed intradermally or intramuscularly.

61. The lipid nanoparticles according to any one of claims 1 to 25, used to induce an immune response against the protein of interest of the lipid nanoparticles in a subject.

62. The lipid nanoparticles of claim 61, wherein the immune response comprises an increase in antibody production.

63. Use of a lipid nanoparticle according to any one of claims 1 to 25 for preparing a medicament for inducing an immune response against the protein of interest of the lipid nanoparticle in a subject.

64. The use according to claim 63, wherein the immune response comprises an increase in antibody production.

65. A method for preventing or treating a disease in a subject, the method comprising administering to the subject a therapeutically effective amount of lipid nanoparticles according to any one of claims 1 to 25.

66. The method of claim 65, wherein the disease comprises an infection.

67. The method of claim 65, wherein the application is performed intradermally or intramuscularly.

68. The lipid nanoparticles according to any one of claims 1 to 25, used for the prevention or treatment of a disease in a subject.

69. The lipid nanoparticles of claim 68, wherein the disease comprises an infection.

70. Use of the lipid nanoparticles according to any one of claims 1 to 25 for the preparation of a medicament for the prevention or treatment of a disease in a subject.

71. The use according to claim 70, wherein the disease comprises an infection.

Citation Information

Patent Citations

  • Lipid-based formulations

    US20030077829A1

  • Liposomal apparatus and manufacturing methods

    US20040142025A1

  • High efficiency encapsulation of charged therapeutic agents in lipid vesicles

    US20050008689A1

  • Systems and methods for manufacturing liposomes

    US20070042031A1

  • Process for amplifying, detecting, and / or-cloning nucleic acid sequences

    US4683195A